Identification and Characterization of a Stem Cell-Like Population in Ovarian Cancer by Sharrow, Allison Catherine
 
 
IDENTIFICATION AND CHARACTERIZATION OF A STEM 















A dissertation submitted to Johns Hopkins University in conformity with the 











 Eighty percent of patients with advanced ovarian cancer show an initial clinical 
response to therapy, but seventy-five percent of these patients eventually relapse.  This 
transient clinical response would be consistent with the cancer stem cell hypothesis.  A 
substantial body of recent evidence supports the cancer stem cell hypothesis in ovarian 
cancer.  However, controversy exists regarding the phenotype of ovarian cancer stem 
cells.  Additionally, their clinical relevance remains unclear. 
 In order to test the hypothesis that ovarian cancer contains a population of 
stem-like cells, aldehyde dehydrogenase 1 high (ALDHhigh) cells from two ovarian 
cancer cell lines with distinct subtypes were examined for cancer stem cell properties.  
Compared to ALDHlow cells, ALDHhigh cells displayed nonadherent growth, an 
absence of contact inhibition, smaller size, quiescence, the ability to regenerate the 
phenotypic diversity of the cell line, in vivo tumorigenicity, multi-drug resistance, and 
gene expression differences consistent with a stem cell phenotype.  Because ALDHhigh 
cells phenotypically resemble cancer stem cells, studying this population in two 
different subtypes may reveal biological properties of ovarian cancer stem cells.  
Differential gene expression suggested that the ALDHhigh population had increased 
tight junction signaling, downregulation of tumor suppressors, increased invasion, and 
decreased coagulation.  No consistent differences were observed in previously 
reported ovarian cancer stem cell markers, hormone receptors, Her-2/neu, CA125 or 
developmental pathways.  The only ABC transporter with consistent upregulation was 
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MDR1.  The ultimate goal of studying ovarian cancer stem cells is to develop 
therapies to eradicate these cells.  Gene expression patterns in ALDHhigh cells 
identified four potential therapeutic targets: mTOR, Her-2/neu, CD47 and FGF18. 
 This project provides further support for the existence of ovarian cancer stem 
cells as well as the use of high aldehyde dehydrogenase 1 activity for their isolation.  
Few studies have comprehensively examined ovarian cancer stem cells from multiple 
subtypes.  This work demonstrated substantial variability between the two studied 
subtypes.  However, those features that were consistent would likely represent 
universal features of ovarian cancer stem cells.  Finally, the potential therapeutic 
targets identified in this study may allow patients with ovarian cancer to achieve 
durable remission. 
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Cancer Stem Cell Hypothesis 
 Current cancer treatments primarily employ three strategies: surgery, radiation 
and chemotherapy.  Each of these approaches has a long history of clinical use.  
Surgical resection was first documented in 1500 B.C1.  Radiation therapy for the 
treatment of cancers not able to be surgically removed was introduced in 19022.  
Chemotherapy began in the middle of the 19th-century with the use of arsenic3.  
However, the basis for modern chemotherapy arose from nitrogen mustard after World 
War II4.  Despite significant refinements to these strategies since their inception, 
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cancer persists as the second leading cause of death in the United States with 38% of 
cancer patients succumbing to their disease5. 
 It is becoming increasingly apparent that simply refining current treatment 
approaches will not substantially impact patient outcomes, and novel approaches are 
necessary.  Many patients show an initial clinical response to standard therapy, often 
achieving complete remission.  However, a significant percentage of patients 
eventually relapse.  The cancer stem cell hypothesis may explain this pattern of 
transient clinical response.  This model proposes that cancer exhibits a similar 
hierarchy as normal tissues in that a small subset of primitive cells (cancer stem cells) 
produces the differentiated progeny that constitute the tumor bulk.  The hypothesis 
further suggests that cancer stem cells persist after standard chemotherapy and initiate 
relapse.  If this cell population could be specifically targeted for treatment, perhaps 
durable remission could be achieved.   
Accepted properties of tissue stem cells provide theoretical support for the 
cancer stem cell hypothesis.  Tissue stem cells typically survive longer than 
differentiated cells, providing sufficient time to accumulate the multiple genetic 
alterations necessary for malignancy6.  Additionally, differentiated cells typically 
undergo only a limited number of cell divisions.  In order to produce the large 
numbers of cells present in a tumor, significant cellular reprogramming of 
differentiated cells would be required to increase their proliferative potential.  In 
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contrast, stem cells possess a substantially greater capacity for cell division, requiring 
fewer alterations to produce a malignant mass.  
Although theoretically supported, insufficient evidence existed to confirm the 
cancer stem cell hypothesis.  The stochastic model serves as an alternative explanation 
for treatment resistance.  This model proposes that chemoresistance may develop in a 
random sampling of the initial population, and any cell remaining after treatment is 
potentially tumorigenic.  The stochastic and cancer stem cell models present opposing 
explanations of cancer with profound implications for research.  Research into the 
development of treatment strategies based on the stochastic model attempt to 
overcome first-order kinetic resistance with approaches such as increasing dose-
intensity.  In contrast, approaching cancer from the perspective of the cancer stem cell 
hypothesis requires identification of the tumorigenic population and the design of 
treatments to specifically eradicate this subset of cells.  Until relatively recently, 
cancer researchers primarily accepted the assumptions of the stochastic model.  
Gradually, though, evidence accumulated in support of the cancer stem cell 
hypothesis, forcing some to reconsider their approach to cancer research. 
Early Evidence of Cancer Stem Cells 
The earliest evidence for the existence of cancer stem cells dates to the 1950’s.  
Observations of chromosome numbers indicated that only a subset of cancer cells 
possessed the capacity for cell division7.  Further analysis of chromosome patterns led 
to the proposal that this population was responsible for metastasis8.  In the 1960’s and 
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1970’s, injections of tritiated thymidine permitted in vivo monitoring of cell division 
in leukemia cells.  Initial results showed that cell division was restricted to the bone 
marrow, which houses hematopoietic stem cells9.  Subsequent analysis revealed the 
existence of a quiescent leukemic population capable of reentering the cell cycle10.  
Thus, research spanning 25 years established heterogeneity in the capacity for 
proliferation within cancer.  Additionally, these findings suggested that 
chemotherapies based on rapid proliferation would not eliminate the quiescent 
population10.   
 Although results to this point were suggestive, the technology available at that 
time could not distinguish between the stochastic and cancer stem cell models.  To 
support the cancer stem cell hypothesis, a tumorigenic population needed to 
demonstrate a stem cell-like phenotype distinct from the nontumorigenic cells.  
Additionally, it was essential that this tumorigenic population produce nontumorigenic 
cells.  Conversely, the nontumorigenic population could not produce tumorigenic 
cells, consistent with the accepted unidirectional nature of differentiation.  Recent 
advancements in technology permitted evaluation of these features.  The introduction 
of cell sorters in the 1970’s permitted isolation of individual cells from a 
heterogeneous sample.  Initially though, cells could only be resolved based on size, 
DNA content or protein content.  The ability to produce protein-specific antibodies in 
1975 revolutionized cell sorting11.  Cells could then be distinguished based on 
expression of particular proteins.  The final necessary advancement was the ability to 
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reliably expand human cells in vivo using xenografts.  With these technologies in 
place, cells could then be isolated based on protein expression, expanded in 
immunocompromised mice, and the resulting cells could be examined.  Using this 
methodology, the specific cellular components of hematopoiesis were identified based 
on cell surface protein expression.   
 The first support to arise from these technological advancements was the 
identification of a subset of leukemia cells that shared cell surface markers with 
normal stem and progenitor cells12.  These results indicated a differentiation hierarchy 
in cancer and implied a stem cell origin for cancer.  What many considered to be 
definitive evidence was presented in 1994 when Lapidot et. al. demonstrated that 
tumorigenicity was restricted to the small subset of leukemia cells that shared cell 
surface expression patterns with normal hematopoietic stem cells13.  With this data, a 
primary feature of the stochastic model was challenged.  Every cell within the cancer 
did not possess the same tumorigenic capacity.  Furthermore, the tumorigenic 
population displayed a stem cell phenotype. 
Modern Evidence of Cancer Stem Cells in Hematological Malignancies 
 The first two cancers in which cancer stem cells were identified were acute 
myeloid leukemia (AML) and chronic myelogenous leukemia (CML).  Initial reports 
indicated that the AML stem cell shared cell surface marker expression with normal 
hematopoietic stem cells (CD34+CD38-), although recent reports have challenged this 
phenotype13-15.  This controversy may be due to reliance on engraftment into 
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immunocompromised mice as the primary assay of tumorigenicity.  Recently, 
persistence of CD34+CD38- AML stem cells has been shown to predict relapse in 
patients16.  This provided the first evidence for the clinical relevance of cancer stem 
cells.  This further showed that clinical correlations might more accurately identify 
tumorigenic populations than xenograft models.  As in AML, the CML stem cell 
shares a phenotype with normal hematopoietic stem cells (CD34+CD71-)17.  
Additional characterization of the CML stem cell reported high aldehyde 
dehydrogenase activity18.   
 Multiple myeloma has generally been considered to be a disease of plasma 
cells.  Clonotypic plasma cells expand in the marrow, producing elevated levels of 
monoclonal antibodies in the blood.  The multiple myeloma stem cell has been shown 
to phenotypically resemble a memory B cell, which differentiates into malignant 
plasma cells19.  Subsequent analysis demonstrated that these clonotypic B cells are 
resistant to chemotherapy drugs used clinically to treat the disease20.  Although 
multiple myeloma research lags behind that of leukemia, preclinical testing of a 
multiple myeloma stem cell-targeted therapy reported promising results.  Multiple 
myeloma stem cells overexpress HLA class I, and an HLA class I-crosslinking 
antibody induced cytotoxicity21.  Further testing should determine the clinical 
effectiveness of this treatment approach. 
 Similar to multiple myeloma, the prominent cells in Hodgkin lymphoma do not 
appear to drive the disease.  In addition to the disease-defining Reed-Sternberg cells, 
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Hodgkin lymphoma contains a population of clonotypic memory B cells22.  These 
cells generate Reed-Sternberg cells in vitro and likely represent the initiating cell in 
Hodgkin lymphoma22.  Characterization of these cells also showed high aldehyde 
dehydrogenase activity22.   
Cancer Stem Cells in Solid Tumors 
 Knowledge of the normal differentiation hierarchy in hematopoiesis facilitated 
the identification of cancer stem cells in hematological malignancies.  In addition to 
characterizing markers of each stage of hematopoiesis, this early work developed 
purification techniques as well as in vivo and in vitro functional assays.  In contrast, 
identification of cancer stem cells in solid tumors is hampered by a lack of 
understanding of their normal counterparts.  Markers of primitive cells must be 
empirically determined, which causes much controversy.  Because of these 
difficulties, the first cancer stem cell in a solid tumor was not described until 2003 
with the identification of tumorigenic breast cancer cells23.  This work required 
evaluation of a variety of cell surface proteins in order to identify those with 
heterogeneous expression.  Cells with high and low levels of expression were then 
compared for tumorigenicity in order to identify breast cancer stem cell markers.  
Since this early work, cancer stem cells have been reported in many types of solid 




Ovarian Cancer Stem Cells 
 Eighty percent of patients with advanced ovarian cancer show an initial clinical 
response to therapy, but seventy-five percent of these patients eventually relapse24.  
This transient clinical response would be consistent with the cancer stem cell 
hypothesis.  The initial response could be attributed to the eradication of the bulk, 
differentiated cells.  The persistence of drug resistant cancer stem cells could be 
responsible for the almost invariable relapse.  Therefore, if the cancer stem cell 
hypothesis is accurate, ovarian cancer will likely contain a population of stem-like 
cells.  A substantial body of recent evidence supports the cancer stem cell hypothesis 
in ovarian cancer.  However, controversy exists regarding the phenotype of ovarian 
cancer stem cells.  Additionally, their clinical relevance remains unclear. 
 In 2005, the first evidence for ovarian cancer stem cells described the 
enrichment of tumorigenic cells from patient samples using non-adherent culture25.  
This initial report initiated a body of research by describing the tumorigenic cells as 
CD44+25.  Several groups isolated CD44+ ovarian cancer cells and reported the stem 
cell features of tumorigenicity, chemoresistance and expression of stem cell factors25-
31.  Clinical evaluation showed that a high percentage of CD44+ cells correlates to 
shorter progression-free survival, but not overall survival32, 33.  However, conflicting 
data challenges the use of CD44 as an ovarian cancer stem cell marker.  Comparisons 
of tumorigenic and nontumorigenic ovarian cancer cells reported no difference in 
CD44 or reduced CD44 expression in the tumorigenic cells34-37.  Furthermore, CD44- 
9 
 
cells generated CD44+ cells, which violates unidirectional differentiation if CD44 
expression identifies ovarian cancer stem cells30. 
 The second report of ovarian cancer stem cells employed side population for 
enrichment34.  The side population phenotype is presumed to be the results of Hoechst 
33342 dye extrusion due to increased expression of drug transporters, especially 
ABCG238, 39.  Ovarian cancer cells isolated based on the side population phenotype 
displayed the stem cell features of tumorigenicity, quiescence, chemoresistance and 
expression of stem cell genes27, 34-36, 40-43.  Additionally, others reported increased 
expression of ABCG2 in their putative ovarian cancer stem cell population29, 35, 44.  
Clinically, relapsed patients demonstrated a higher percentage of side population cells 
compared to patients with primary, chemonaïve disease41.  Although many reports 
support the use of side population as an ovarian cancer stem cell marker, conflicting 
reports also challenge this assertion.  A survey of clinical samples only detected side 
population cells in one third of patients45.  If side population enriches for ovarian 
cancer stem cells, all patients should possess this population.  Although expression of 
ABCG2 is believed to cause the side population phenotype, expression of ABCG2 
does not correlate with tumorigenicity40, 46.  Finally, Hoechst 33342 dye induces 
cytotoxicity, causes DNA mutations and disrupts the cell cycle47.  Because side 
population cells more efficiently remove the dye, their apparent increased 




The use of CD133 expression as an ovarian cancer stem cell marker began 
with the observation that CD133+ primary tumor cells produce more cells than CD133- 
cells48.  Subsequent work demonstrated multiple stem cell features in CD133+ cells, 
including tumorigenicity, drug resistance, the ability to generate CD133- cells, and 
increased expression of stem cell genes44, 49-53.  Evaluation of clinical specimens 
showed an increase in the percentage of CD133+ cells in relapse tumors compared to 
primary tumors54.  Furthermore, patients with CD133+ cells showed a slightly poorer 
progression-free and overall survival than patients without CD133+ cells55.  However, 
for every stem cell feature reported in CD133+ cells, conflicting data exists.  Only 30-
70% of patients possess any CD133+ tumor cells55, 56.  As with the side population 
phenotype, all patients should possess ovarian cancer stem cells.  Furthermore, CD133 
expression does not correlate with tumorigenicity34, 46.  Both CD133+ and CD133- 
cells produce tumors with heterogeneous CD133 expression, which would not occur if 
CD133 expression decreases with differentiation50.  Finally, the percentage of CD133+ 
cells in a patient’s tumor provides no prognostic value57, 58. 
More recently, CD24 expression has been proposed to enrich for ovarian 
cancer stem cells.  CD24+ cells exhibited the stem cell features of tumorigenicity, 
chemoresistance, the ability to produce CD24- cells, and expression of stem cell 
genes35, 59, 60.  However, a conflicting report showed stem cell features in CD24- cells 




Early reports of ovarian cancer stem cells indicated higher levels of KIT 
(CD117) expression, yet very few studies exclusively studied KIT.  The one study that 
specifically compared KIT+ to KIT- cells demonstrated tumorigenicity in the KIT+ 
population61.  They additionally established a correlation between patients with 
detectable KIT+ cells and chemoresistance61.  The only other evidence for KIT as an 
ovarian cancer stem cell markers depends on measuring KIT expression in 
tumorigenic ovarian cancer cells isolated by other means.  While some studies found 
increased KIT expression in tumorigenic cells, other studies detected the same or 
lower levels of KIT25, 29, 34, 35, 44, 52.  Furthermore, only 40-45% of tumor samples 
contain any KIT+ cells56, 61.   
The numerous reports of high aldehyde dehydrogenase 1 activity (ALDHhigh) 
in normal and malignant stem cells have led some to propose that ALDHhigh ovarian 
cancer cells represent ovarian cancer stem cells62-68.  ALDHhigh ovarian cancer cells 
display tumorigenicity, the ability to generate ALDHlow cells, and chemoresistance51, 
56, 69-73.  Clinically, higher percentages of ALDHhigh cells correlate to poorer 
progression-free and overall survival56, 69-71.  However, one study showed an improved 
prognosis with higher percentages of ALDHhigh cells74.  In addition to this conflicting 
report, other inconsistencies exist.  One study could not detect ALDHhigh cells in 
23.1% of 65 ovarian cancer samples, however other studies detected ALDHhigh cells in 
all 18 and 25 samples tested51, 56, 69.  Finally, some reports detected ALDHhigh cells in 
xenografts from ALDHlow cells51, 71. 
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The preponderance of evidence supports the existence of ovarian cancer stem 
cells.  However, uncertainty remains surrounding the ideal marker for their isolation.  
For each proposed marker, reports exist both in support and opposition, and very few 
studies compare multiple markers.  One study measured expression of CD44, CD133, 
CD24, KIT and ALDH1 in 13 primary tumors and five ascites samples.  The only 
marker with limited expression in all samples was ALDH156.  Another study examined 
CD44 and ALDH1 expression in tumorigenic cells.  Despite stable CD44 expression, 
the loss of ALDH1 activity correlated with reduced tumorigenicity30.  These two 
studies support the use of ALDH1 expression as a marker of ovarian cancer stem cells 
over other proposed markers.  Finally, expression of CD133 may enrich for 
endothelial progenitor cells to support the growth of the tumor, rather than ovarian 
cancer stem cells75.  While this limited evidence begins to clarify the value of distinct 
ovarian cancer stem cell markers, further research is required. 
Research Plan 
 I sought to test the hypothesis that ovarian cancer contains a population of 
stem-like cells.  I selected two models of ovarian cancer for this study.  The first is a 
rat model of ovarian cancer, termed FNAR-C1, that is described in detail in Chapter 
Two.  Briefly, this spontaneously occurring ovarian tumor expands in vivo and forms 
tumors in immunocompetent rats.  Histological evaluation determined that FNAR-C1 
most closely resembles the endometrioid subtype.  In order to control for potential 
subtype differences, the SKOV3 cell line was also utilized.  The subtype of SKOV3 
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cells has been described as both clear cell and serous76, 77.  In addition to the parental 
SKOV3 line, I also employed a taxol-resistant SKOV3 subline.   
 Next, I determined the methodology for isolation of putative ovarian cancer 
stem cells.  At the initiation of this project, only two reports described stem-like cells 
in ovarian cancer.  The isolation methods used nonadherent growth and side 
population.  Tumorigenic cells expressed variable levels of cancer stem cell markers 
previously reported for other cancers (KIT, CD44, CD24 and CD133).  Based on these 
results, I selected a marker not examined in these studies.  High aldehyde 
dehydrogenase 1 (ALDH1) activity has been reported in many normal and malignant 
stem cells62-68.  The ALDH superfamily of enzymes oxidizes intracellular aldehydes.  
Specifically, the ALDH1 family converts vitamin A into retinoic acid.  On this basis, I 
chose high ALDH1 activity as a putative marker of ovarian cancer stem cells.  In order 
to isolate viable cells on the basis of enzyme activity, I used the Aldefluor reagent 
developed in the laboratory of my advisor78.  Aldefluor serves as a fluorescent 
substrate of ALDH1.  BODIPY-acetaldehyde freely diffuses into cells, where ALDH1 
converts it to BODIPY-retinoic acid.  Once modified by ALDH1, Aldefluor can no 
longer exit the cell through passive diffusion.  Fluorescence accumulates in cells with 
high ALDH1 activity, which can then be isolated with a cell sorter. 
 Once ovarian cancer cells were isolated based on ALDH1 activity, I tested the 
populations for cancer stem cell properties.  On the basis of these tests, I confirmed 
that ALDHhigh cells represent a less differentiated population in ovarian cancer than 
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ALDHlow cells.  Next, I characterized expression differences between these 
populations to better understand the biology of ovarian cancer stem cells.  Finally, 
expression patterns revealed potential therapeutic targets to more effectively treat 
ovarian cancer. 
 This project contributes to the understanding of ovarian cancer in several ways.  
First, FNAR-C1 cells provide a novel model for the study of ovarian cancer with 
advantages over current animal models.  This model circumvents current controversy 
surrounding assessment of in vivo tumorigenicity in immunocompromised animals 
with its transplantability into immunocompetent rats.  The cell line expands in vitro, 
allowing for more detailed analysis.  Because the tumor arose spontaneously, it lacks 
artificial genetic manipulations that may not occur in the human disease.  Overall, this 
model may serve as a valuable experimental model to improve understanding of the 
biology of ovarian cancer. 
 This project further supports the existence of ovarian cancer stem cells and the 
use of high aldehyde dehydrogenase activity as an ovarian cancer stem cell marker.  
Comparison of expression differences between stem and differentiated cells provides 
insight into the biological differences between these cell populations.  Additionally, 
the use of models from two discrete ovarian cancer subtypes controls for potential 
subtype-specific differences.  Since few studies compare the various proposed ovarian 
cancer stem cell markers, analyses included all previously reported markers.  Finally, 
this project proposes potential therapeutic targets based on examination of expression 
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patterns, which has not yet been explored in detail.  Thus, this project expands 




Ovarian cancer contains a population of cells with stem-like characteristics that is 
responsible for relapse. 
Research Objectives: 
1.  Isolate and validate cancer stem cells in ovarian cancer 
2.  Characterize cancer stem cells in ovarian cancer 
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Background  
 Ovarian cancer is the fifth most commonly diagnosed cancer in women and the 
fourth most common cause of death from cancer 79.  The high mortality can be 
attributed to the high percentage of affected women presenting at an advanced stage, 
with spread within the peritoneal cavity 80, 81.  With current therapies, including 
surgical debulking and platinum-based chemotherapy, patients in stage III or stage IV 
only have a 20% chance of long-term survival 80, 81.  Better understanding ovarian 
carcinoma biology, as well as the development of new therapies for the disease, has 
been hampered by the lack of suitable animal models.  
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 Current ovarian cancer models fall into three broad categories: rare 
spontaneous carcinomas, induced tumors, and human xenografts 82. Although these 
models have allowed researchers to gain valuable insights into the biology of ovarian 
cancer, each model exhibits important limitations 82, 83.  Spontaneous ovarian cancer 
has been observed in mice, rats, and hens 84-86.  The drawback to these models is that 
the cancers tend to occur at an advanced age and at similar low frequencies as in 
humans.  The low incidence and the length of time required for the development of 
these tumors render them of limited use for studying the biology and treatment of 
ovarian carcinoma.  Induced tumor models circumvent these problems but create their 
own artificial systems, which may not accurately reflect the human disease.  In one 
model of in vitro transformation, ovarian surface epithelium cells are subcloned until 
they exhibit the loss of contact inhibition, the capacity for substrate-independent 
growth, cytogenetic abnormalities, and the ability to form tumors when injected 
subcutaneously and/or intraperitoneally into athymic mice 87.  This model, though, 
fails to account for critical interactions between the cancer cells and the host.  Also, it 
is uncertain if these cells or their malignant transformation are representative of 
normal human cells or clinical disease.   
Animal models have been generated by expressing simian virus 40 large T 
antigen 88, by inactivating p53 and Rb1 89, by inactivating p53 and activating an 
oncogene 90, and through hormone treatment 91-93.  The high rate of cancer 
development in these animals makes these models attractive, but they may not reliably 
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represent human cancer because a majority of these genetic changes usually do not 
occur in patients.  Xenografts of human cancers have undergone continuous 
improvement over the past twenty years 94-97.  These models allow for direct 
examination of the human cancer but do not allow the study of the early stages of the 
cancer.  These models also rely on an immune-deficient host, which eliminates the 
interaction between the cancer and the immune system.  
We present a new model of ovarian carcinoma, designated FNAR, that 
spontaneously developed in an untreated, previously normal Lewis rat.  The tumor 
could be serially passaged both in vivo as malignant ascites in rats and in vitro.  
Importantly, the biologic characteristics of the tumor closely paralleled one type of 
human ovarian carcinoma. 
Methods 
 Animals.  Female Lewis strain rats aged 4-6 weeks (purchased from Charles 
River Breeding Laboratories, Inc., Wilmington, MA) were kept in sterile micro-
isolator cages and fed food and water ad libitum.  The institutional guidelines of Johns 
Hopkins University concerning the care and use of research animals were followed.  
The animals were challenged intraperitoneally with graded numbers of FNAR cells 
and monitored daily for abdominal swelling.  At various intervals after tumor 
challenge or when animals appeared moribund (pallor, lethargy, and marked 
abdominal distension), the animals were sacrificed by CO2 asphyxiation and the cells 
within the peritoneal cavity harvested by flushing the abdomen with 35 milliliters of 
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sterile phosphate buffered saline (PBS, Grand Island Biological Co., Gibco BRL, 
Grand Island, NY).  At sacrifice, the animals were examined for tumor growth and 
tissues taken for histological examination.  
In vitro propagation and growth curve.  A cell line (FNAR) that grows in vitro 
as an adherent monolayer was established by culture in RPMI 1640 (Gibco) 
supplemented with 10% fetal calf serum in 30 ml tissue culture flasks (Corning Flask 
3056, Corning Inc., Corning NY).  Cells used for experiments were low passage and 
maintained in culture for one to three months.  The doubling time of the cell line was 
measured by plating 104 cells into macrotiter wells then harvesting and counting at 
19.5, 43.5, and 115.5 hours. 
Flow Cytometric Analysis.  Flow cytometry was utilized to assess in vitro 
FNAR cells for expression of known phenotypic markers.  Briefly, 5 x 105 tumor cells 
were incubated in polystyrene tubes.  Analysis of the intracellular antigens estrogen 
receptor α, progesterone receptor, and androgen receptor first required fixation in 2% 
formaldehyde (Polysciences, Warrington, PA) in phosphate buffered saline (PBS, 
Gibco Invitrogen, Carlsbad, CA) for 15 minutes at 4°C followed by permeabilization 
with 0.1% Triton-X-100 (Sigma-Aldrich, St. Louis, MO) in PBS for 15 minutes at 
4°C.  The cells were then incubated for 30 minutes at 4°C with commercially 
purchased murine monoclonal antibodies.  The concentrations of antibodies used are 
as follows: estrogen receptor (ER) α at 8 µg/106 cells (Abcam, Cambridge, MA), 
progesterone receptor (PR) at 16 µg/106 cells (Affinity Bioreagents, Golden, CO), or 
20 
 
androgen receptor (AR) at 2 µg/106 cells (Pharmingen, San Diego, CA).  The cells 
were washed and counterstained with phycoerythrin (PE) rat anti-mouse IgG1 (Becton 
Dickinson, San Jose, CA) at 125 ng/106 cells for 30 minutes at 4°C.  Commercially 
purchased murine monoclonal antibody to the rat c-neu oncogene product 
(Calbiochem, San Diego, CA) was used at 1 µg/106 cells and was counterstained with 
PE rat anti-mouse IgG2a+b (Becton Dickinson, San Jose, CA) at 30 ng/106 cells for 30 
minutes at 4°C.  Tumor cells incubated with secondary antibody alone served as a 
negative control.  Epithelial cell adhesion molecule (EPCAM) expression was 
analyzed using a PE-conjugated antibody (Santa Cruz, Santa Cruz, CA) at 1 µg/106 
cells with mouse IgG1-PE as a negative control (Becton Dickinson, San Jose, CA).  A 
commercially available rabbit polyclonal antibody to CA125 (Abbiotec, San Diego, 
CA) was used at 2 µg/106 cells and counterstained with 1 µg/106 cells APC goat anti-
rabbit IgG (Invitrogen Molecular Probes, Carlsbad, CA).  The cells were analyzed on 
a Becton-Dickinson FACSCalibur flow cytometer and data was analyzed using 
FlowJo (Tree Star, Inc, Ashland, OR).  
 Immunocytochemistry.  FNAR cells were plated onto four-well CultureSlides 
(BD Falcon, San Jose, CA).  Cells were fixed in 2% formaldehyde in PBS for 20 
minutes followed by permeabilization in 0.5% Triton X-100 in PBS for 10 minutes.  
Cells were then incubated with a mouse monoclonal antibody to beta-catenin 
conjugated to Cy3 (Abcam, Cambridge, MA) at 6 µg/ml for one hour and 
counterstained with 500 ng/ml DAPI for five minutes (Invitrogen Molecular Probes, 
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Carlsbad, CA).  Images were captured using the Nikon Eclipse E800 (Tokyo, Japan) at 
200x magnification with standard filters for DAPI and Cy3, the DS-QiMc digital 
camera (Nikon, Tokyo, Japan), and the Advanced Research Elements AR 3.0 software 
(Nikon, Tokyo, Japan). 
Gene Expression Analysis by cDNA Microarrays.  RNA was extracted and 
purified from cell lysates of 1-5 x 105 in vitro FNAR tumor cells and the REH cell line 
of normal rat endothelial cells, as a control, with 500 µl Trizol reagent (Invitrogen, 
Carlsbad, CA).  Tissue samples were frozen in liquid nitrogen and pulverized with a 
mortar and pestle.  The powder was dissolved in Trizol and centrifuged.  Purified 
RNA was dissolved in 20µl diethyl-pyrocarbonate-treated distilled water.  The 
resulting RNA was analyzed at the Johns Hopkins microarray core.  RNA from 
control and experimental samples was processed using the RNA amplification 
protocol described by Affymetrix (Affymetrix Expression Manual).  Briefly, 5 µg of 
total RNA was used to synthesize first strand cDNA using the SuperScript Choice 
System (Invitrogen, Carlsbad, California) and oligonucleotide primers with 24 oligo-
dT plus the T7 promoter (Proligo LLC, Boulder, Colorado).  Following the double 
stranded cDNA synthesis, the product was purified by phenol-chloroform extraction 
and biotinilated anti-sense cRNA was generated through in vitro transcription using 
the BioArray RNA High Yield Transcript Labeling Kit (ENZO Life Sciences Inc., 
Farmingdale, New York).  Fifteen µg of the biotinilated cRNA was fragmented at 
94°C for 35 minutes in buffer (100mM Tris-acetate, pH 8.2, 500mM potassium 
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acetate, and 150mM magnesium acetate), and 10µg of total fragmented cRNA was 
hybridized to the Affymetrix GeneChip rat 230 2.0 array (Santa Clara, CA) for 16 
hours at 45ºC with constant rotation (60 rpm).  Affymetrix Fluidics Station 450 was 
then used to wash and stain the chips with a streptavidin-phycoerythrin conjugate.  
The staining was then amplified as follows: blocking was performed using goat IgG, 
then a biotinilated anti-streptavidin antibody (goat) was bound to the initial staining, 
and amplification was completed by the addition of a streptavidin-phycoerythrin 
conjugate.  Fluorescence was detected using the Affymetrix 3000 7G GeneArray 
Scanner and image analysis of each GeneChip was done through the GeneChip 
Operating System 1.4.0 (GCOS) software from Affymetrix using the standard default 
settings.  For comparison between different chips, global scaling was used to scale all 
probesets to a user defined target intensity (TGT) of 150. 
Quantitative RT-PCR for Cytokine Expression.  Quantitative RT-PCR 
(Taqman, Applied Biosystems, ABI, Foster City, CA) was utilized to assess levels of 
cytokine mRNA transcripts of in vitro FNAR cells as previously described 98.  The 
oligonucleotide primers and fluoresceinated probes for the cytokine genes (IL-6, IL-
12, and IL-18), ER, PR, and stathmin were purchased from ABI.  Data were analyzed 
in real-time with Sequencer Detection version 1.6 software, with the results 
normalized against mRNA transcripts for the housekeeping gene glyceraldehyde-3-





Description of proband. Examination of a normal female Lewis rat sacrificed 
for harvesting normal splenic T cells showed a spontaneously occurring tumor 
(approximately 0.5 cm3) derived from the left ovary and attached to and invading the 
abdominal wall (Figure 2.1A).  In addition, tumor studding was observed at several 
sites on the wall of the peritoneum, and ascites was present.  Histologic evaluation 
revealed an epithelial neoplasm with features most consistent with an adenocarcinoma 
(Figure 2.1B).  The tumor was composed of nests displaying admixed cribriform and 
solid architecture.  The tumor cells had modest amounts of amphophilic/eosinophilic 
cytoplasm and relatively uniform, moderately atypical oval nuclei that were 
predominantly vesicular to modestly hyperchromatic with small nucleoli.  Occasional 
mitotic figures and apoptotic bodies were noted, as was focal necrosis.  Based on  
analogy to human ovarian epithelial tumors, this tumor most closely resembled a  
moderately differentiated endometrioid carcinoma (a cribriform variant of that 
subtype, with cells being less columnar than the classical human endometrioid 
carcinoma), with disease distribution paralleling a typical high-stage (human FIGO 
stage IIIB) ovarian carcinoma.  Lymphocyte infiltration into the tumor mass was 
minimal at best, although numerous lymphocytes were present in the peritoneal fluid.  
The tumor was excised and pushed through a 100 micron wire mesh screen to obtain a 




Figure 2.1: Gross and Histologic Examination of Proband 
Intraperitoneal tumor arising spontaneously in a Lewis rat has pathologic appearance of an ovarian 
adenocarcinoma. (A) Proband shows tumor of the left ovary and intraperitoneal tumor studding.  (B) 
Histology reveals an adenocarcinoma. 
In vivo and in vitro growth characteristics.  Normal Lewis rats were given 
either intraperitoneal (IP) or subcutaneous injection of graded numbers (5 x 104, 1 x 
105, 5 x 105, or 1 x 106) of tumor cells.  The animals were monitored daily for overall 
general health as well as degree of abdominal extension.  The tumor repeatedly failed 
to grow subcutaneously, even with the administration of systemic immunosuppression 
(Cyclosporine, 10 mg/kg/d) or passage into thymectomized animals.  However, all rats 
became moribund at 150-160 days after IP injection with 5 x 105 or 1 x 106 cells 
(Table 2.1).  Rats injected with 1 x 105 cells became moribund around 175 days.  Rats 
receiving IP injections of 5 x 104 cells generally did not appear ill by 6 months, but 
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tumor cells were detected in the peritoneal cavity when sacrificed on day 175.  Tumor 
growth recapitulated that seen in the initial rat with IP tumoral masses adhering to all 
of the visceral organs and the abdominal wall.  Histologically, the tumors appeared to 
be of epithelial origin.  Affected rats also showed enlargement of the ovaries and 
fallopian tubes, with a marked increase in vascularization.  Successful serial passage 
was conducted by IP challenge with 1 X 105 tumor cells harvested by flushing of the 
peritoneal cavity.   
Table 2.1: Survival After Intraperitoneal Injection of FNAR Cells 
The survival time of rats corresponds to the number of FNAR cells injected intraperitoneally.  Animals 
were observed daily for general health and abdominal extension.  The animals were sacrificed upon 
becoming moribund, which was characterized by extreme lethargy, paleness, and abdominal extension.  
The abdominal cavity was examined histologically for the presence of tumor cells in the peritoneal fluid 
and for tumor masses attached to the visceral organs and the abdominal wall. 
The doubling time of the FNAR cell line was measured by plating 104 cells 
into macrotiter wells then harvesting and counting at 19.5, 43.5, and 115.5 hours 
(Figure 2.2).  The slope of the line of log number of tumor cells versus hours estimates 
a doubling time of 22.9 hours. 
Survival Following Tumor Challenge 
No. of Cells Injected No. of Animals Survival – Days (No. of Animals) 
5 X 104 N = 6 175 (6) 
1 X 105 N = 8 150 (4) 155 (3), 160 (1) 
5 X 105 N = 6 155 (2), 160 (4) 
1 X106 N = 6 150 (5), 152 (1) 
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Figure 2.2: In Vitro Growth Characteristics 
In vitro doubling time was measured by 
plating 104 cells into large flat bottom 
macrotiter wells.  At the designated 
intervals, cells were harvested and 
counted.  Data is presented as log 
number of tumor cells versus growth 
time.  The slope of the line represents an 
estimate of the doubling time. 
 
Biological characterization of FNAR.  ER is detected in 60-90% of ovarian 
carcinomas 99-103, 25-50% express PR 99, 101-104, and 45% expressed both 101, 103.  AR is 
expressed in 50-70% of ovarian carcinomas 102, 104.  Accordingly, in the appropriate 
clinical and pathologic setting, sex hormone receptor expression is characteristic of 
ovarian carcinoma 103, 105.  The tumor expressed ER, PR, and AR by flow cytometry 
(Figure 2.3A-C), with ER and PR confirmed by PCR (data not shown).  The tumor 
also expressed her-2/neu (Figure 2.3D), which is expressed in 25-35% of ovarian 
carcinomas 106, 107.  The epithelial origin of this carcinoma was confirmed by its 
expression of EPCAM (Figure 2.3E).  Consistent with previous reports of 
endometrioid carcinoma, FNAR cells display cell-surface expression of CA125 
(MUC16, data not shown) 108.  FNAR cells also show nuclear staining of ß-catenin 
(Figure 2.4), which is strongly associated with the endometrioid subtype 109. 
27 
 
Figure 2.3: FNAR Expression of ER, PR, AR, Her-2/neu, and EPCAM 
 
Flow cytometric evaluation of FNAR 
cells for expression of (A) ER, (B) PR, 
(C) AR, (D) Her-2/neu, and (E) 
EPCAM.  In all five graphs, isotypic 
control is shown with a solid line and the 








Figure 2.4.  FNAR Expression of ß-catenin 




Gene expression profiling demonstrated that FNAR gene expression was 
similar to that reported for human ovarian carcinoma (Table 2.2).  Metallothioneins 
are generally not found at immunohistochemically detectable levels in normal cells, 
but their expression increases in ovarian carcinoma with increasing grade 110-112.  
Metallothionein I was overexpressed 11.38-fold in FNAR cells when compared to 
endothelial cells, and metallothionein II showed 3.56-fold increased expression.   
Table 2.2: Gene Chip Analysis of FNAR 
Gene Expression Profiling of FNAR Cells 
Gene Description EST Accession # Relative Expression 
Metallothionein I AW141679 11.38 
Metallothionein II AW916991 3.56 
Thioredoxin AW140607 3.07 
Stathmin BF281472 3.23 
b-myb RGIAC37 3.33 
Gene chip analysis of FNAR shows similarities to human ovarian carcinoma.  RNA was harvested from 
FNAR and REH endothelial cell lines and analyzed by GeneChip at a Johns Hopkins core facility.  Data 
are presented as the relative expression of the gene in FNAR compared to expression in endothelial 
cells. 
Thioredoxin expression correlates with cis-diaminedichloroplatinum resistance 113 and 
is expressed in FNAR cells 3.07-fold higher than in endothelial cells.  Stathmin 
regulates microtubules during the formation of the mitotic spindle and is not expressed 
at detectable levels in normal cells; however, high-level expression is generally seen in 
ovarian carcinoma 114-116.  Accordingly, stathmin expression was 3.23-fold higher in 
FNAR cells than in endothelial cells.  This data was confirmed by PCR (data not 
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shown).  A nuclear factor that it is involved in cell cycle progression, b-myb, is also 
highly expressed in both FNAR cells (3.33-fold) and human ovarian carcinoma 117.  
High levels of interleukin-6 (IL-6), a proinflammatory cytokine and 
hematopoietic growth factor, are found in both normal ovarian epithelium and human 
ovarian carcinoma 118, 119.  Interleukin-18 (IL-18) is a proinflammatory cytokine that 
stimulates interferon-γ production.  Ovarian carcinoma expresses IL-18, but it is 
predominantly the pro-IL-18 form 120.  Interleukin-12 (IL-12) is a cytokine that 
encourages a Th1 immune response.  IL-12 has been detected in ascites fluid and 
serum of ovarian cancer patients 121, although no reports have examined the expression 
of IL-12 by the ovarian carcinoma cells themselves.  Expression of all three cytokines 
by FNAR cells was detected by real time RT-PCR (Figure 2.5).   
Figure 2.5: FNAR Expression of IL-6, IL-12, and IL-18 
 
FNAR tumor cells express IL-6, IL-12, 
and IL-18.  Expression was assessed by 








We present here a model of ovarian carcinoma, designated FNAR, that arose 
spontaneously in a normal Lewis rat.  Importantly, FNAR’s biology closely parallels 
the human disease.  IP transplantation into rats produces malignant ascites and 
peritoneal carcinomatosis, leading to death at 5-6 months.  The tumor only develops in 
the peritoneal cavity, suggesting the tumor microenvironment is intact during 
formation. Cells from the tumor can be easily passaged in vitro, and the cell line 
shows similar growth characteristics when returned to rats.  Its morphology and 
expression of EPCAM are consistent with an epithelial carcinoma, and like human 
ovarian carcinoma, it expresses her-2/neu, sex hormone receptors, and characteristic 
cytokines.  FNAR also displays a similar gene expression pattern to the human 
disease.  Consistent with the endometrioid subtype, FNAR cells show cell-surface 
expression of CA125 and nuclear expression of ß-catenin.   
 The FNAR model may address many of the limitation of current model 
systems for ovarian carcinoma.  Rats transplanted with FNAR consistently become 
moribund by 5-6 months, avoiding the low frequency and long latency of spontaneous 
animal models.  Xenografts of primary human tumors in immunodeficient mice are 
perhaps the most attractive current model 94-97.  Although spontaneous human cancers 
can be studied and used to test treatments in these mice, the study of 
immunotherapeutic approaches is problematic.  Conversely, FNAR develops in 
immunocompetent rats, allowing the study of immunotherapeutic approaches.  The 
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expression of all three sex hormone receptors and her-2/neu also allows for 
manipulations of these pathways using this model.  However, the application of this 











Cell Lines and Culture 
 FNAR-C1 rat ovarian cancer cells were obtained as previously described122.  
The human ovarian cancer cell line SKOV3 and taxol-resistant SKOV3 cells were the 
kind gifts of Drs. Alexander Stoeck, Tian-Li Wang and Ie-Ming Shih.  Cells were 
maintained in two different media.  The first was KnockOut medium, which is a 
proprietary serum-free medium designed for culturing embryonic stem cells in an 
undifferentiated state and consists of KnockOut DMEM (Life Technologies, Grand 
Island, NY) with 10% KnockOut Serum Replacement (Life Technologies, Grand 
Island, NY), 2 mM L-glutamine (Life Technologies, Grand Island, NY), 100 U/mL 
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penicillin (Life Technologies, Grand Island, NY) and 100 µg/mL streptomycin (Life 
Technologies, Grand Island, NY).  Cells were also cultured in standard medium: 
RPMI (Life Technologies, Grand Island, NY) with 10% FBS (Sigma, St. Louis, MO), 
2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin.  For reasons 
described in Chapter 4, standard medium will hereafter be referred to as differentiation 
medium.  Taxol-resistant SKOV3 cells were continuously incubated with 33.3 nM 
paclitaxel (taxol; Sigma-Aldrich, St. Louis, MO).  Cells were expanded in vented 
T175 tissue culture flasks. 
Cell Sorting 
 For cell sorting, adherent cells were released from flasks with 0.05% trypsin-
EDTA (Life Technologies, Grand Island, NY) and pipetting.  Cells were stained with 
Aldefluor reagent (STEMCELL Technologies Inc., Vancouver, BC, Canada) using the 
manufacturer’s protocol then stained with 0.5-1 µg/mL propidium iodide (Sigma-
Aldrich, St. Louis, MO) for 5 minutes.  FNAR-C1 cells grown in KnockOut medium 
were sorted using a MoFlo cell sorter (Beckman Coulter, Miami, FL).  Because of 
substantial death after sorting, these cells were allowed to recover before use in the 
following experiments: doubling time, cell cycle analysis and drug resistance.  No 
greater than 3x106 cells were plated in KnockOut medium in vented T175 tissue 
culture flasks for three to four days.  After this time, cells were released from the 
flasks using trypsin and pipetting as described above.  All other cells were sorted using 
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a FACSAria II cell sorter (BD Biosciences, San Jose, CA).  Representative images 
were generated using FlowJo 8 (Tree Star, Inc, Ashland, OR). 
Photomicrographs 
 Sorted cells were plated into 6-well tissue culture plates.  When cells were at 
the desired level of confluency, photomicrographs were generated using a Nikon 
Eclipse TE2000E with 4x, 10x and 20x phase contrast objectives; Nikon DS-Qi1Mc 
CCD camera; and Nikon NIS Elements 3 software (Nikon Instruments Inc., Melville, 
NY).   
Cell Size Analysis 
 Unsorted cells were trypsinized then stained with Aldefluor and propidium 
iodide as described above.  Cells were analyzed on a FACSCalibur flow cytometer 
(BD Biosciences, San Jose, CA) and plots were generated using FlowJo 8. 
Doubling Time 
 Sorted cells were plated into vented T25 tissue culture flasks with the medium 
they were cultured in prior to sorting.  At 24-hour intervals ranging from 24 to 120 
hours, cells were released from flasks with trypsin and pipetting as described above.  
FNAR-C1 cells grown in KnockOut medium and sorted for Aldefluor high tended to 
form aggregates, which were disrupted after trypsinization using Accumax and 
pipetting (EMD Millipore, Billerica, MA).  Viable cells were counted by mixing cells 
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with an equal volume of trypan blue (Life Technologies, Grand Island, NY) and 
pipetting onto a hemacytometer (Hausser Scientific, Horsham, PA).  Ten 1 mm2 
squares were counted and averaged to obtain the final cell count.  Time points that 
appeared to be in lag phase or plateau phase were excluded from the doubling time 
calculations.  Doubling times were calculated using an online doubling time calculator 
(Roth V. 2006 http://www.doubling-time.com/compute.php).  Graphs were generated 
using Excel 2008 for Mac (Microsoft, Redmond, WA).   
Cell Cycle Analysis 
 Sorted cells were allowed to recover overnight after sorting.  No more than 
5x105 Aldefluor low FNAR-C1 or SKOV3 cells were plated into vented T75 tissue 
culture flasks with differentiation medium.  1.75x105 Aldefluor high taxol-resistant 
SKOV3 cells were plated in a vented T25 tissue culture flask with KnockOut medium.  
Cells were released from flasks using trypsin and pipetting as described above.  
Aldefluor high FNAR-C1 cells were harvested from recovery flasks as described in 
Cell Sorting.  No greater than 2.5x105 cells were resuspended in 2 ml ice-cold PBS 
(Life Technologies, Grand Island, NY).  Cells were fixed with the dropwise addition 
of 1 ml ice-cold methanol (Fisher, Waltham, MA) then incubated overnight at 4°C.  
Cells were rehydrated in PBS then stained with 50 µg/ml propidium iodide and 10 
µg/ml RNase (Roche, Indianapolis, IN) in PBS for 30 minutes at room temperature.  
Data was collected on a FACSCalibur flow cytometer and analyzed using FlowJo 8. 
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Microarray and Pathway Analysis 
 Cells were sorted into RNAprotect Cell Reagent (Qiagen, Valencia, CA) to 
preserve RNA.  Total RNA was isolated from sorted cells using the RNeasy Mini Kit 
with QIAshredder columns (Qiagen, Valencia, CA).  Quality assessment and 
microarray analysis was performed at The Sidney Kimmel Cancer Center Microarray 
Core Facility at Johns Hopkins University, supported by NIH grant P30 CA006973 
entitled Regional Oncology Research Center.  RNA quality was determined with a 
NanoDrop ND-1000 spectrometer (Thermo Scientific, Waltham, MA) for OD260/280 
and OD260/230 ratio and a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
CA).   
The following rat samples were analyzed: FNAR-C1 grown in differentiation 
medium and sorted for Aldefluor low, and FNAR-C1 grown in KnockOut medium 
and sorted for Aldefluor high.  Rat samples were analyzed using the Rat Gene 
Expression Microarray 4x44K v3 (Agilent Technologies, Santa Clara, CA).  Sample 
amplification and labeling procedures were carried out using the Low RNA Input 
Fluorescent Linear Amplification Kit (Agilent Technologies, Santa Clara, CA) with 
minor modifications.  Briefly, 0.4 µg total RNA was reverse-transcribed into cDNA 
by MMLV-RT using an oligo(dT) primer that incorporates a T7 promoter sequence 
(System Biosciences, Mountain View, CA).  The cDNA was then used as a template 
for in vitro transcription in the presence of T7 RNA polymerase and Cyanine-3 (Cy3) 
labeled CTP (Perkin Elmer, Waltham, MA).  Labeled cRNA was purified using the 
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RNeasy Mini Kit.  RNA spike-in controls (Agilent Technologies, Santa Clara, CA) 
were added to RNA samples before amplification and labeling according to 
manufacturer’s protocol.  0.825 µg of each Cy3-labeled sample was used for 
hybridization at 65ºC for 17 hours in a hybridization oven with rotation.  After 
hybridization, microarrays were washed and dried according to the Agilent microarray 
processing protocol using Stabilization and Drying Solution (Agilent Technologies, 
Santa Clara, CA).  Microarrays were scanned using an Agilent G2565AA Scanner 
controlled by Agilent Scan Control 7.0 software (Agilent Technologies, Santa Clara, 
CA).  Data were extracted with Agilent Feature Extraction 9.5.3.1 software (Agilent 
Technologies, Santa Clara, CA).   
The following human samples were analyzed: SKOV3 grown in differentiation 
medium and sorted for Aldefluor low, and taxol-resistant SKOV3 grown in KnockOut 
medium and sorted for Aldefluor high.  Human samples were analyzed using the 
Human HT-12 v4 bead chip (Illumina, San Diego, CA).  500 ng of total RNA from 
each sample was amplified and labeled using the Illumina Total Prep RNA 
Amplification Kit (Ambion, Austin, TX) as described in the instruction manual.  For 
array assay, 750 ng biotin-labeled cRNA was combined with hybridization buffer and 
hybridized to the array at 58°C for 16-20 hours.  After hybridization, the hybridization 
cartridge was disassembled and the array was washed with buffer at 55°C and blocked 
at room temperature.  Bound biotinylated cRNA was stained with streptavidin-Cy3 
and then washed.  Dried arrays were stored in a dark box until scanned with the iScan 
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System (Illumina, San Diego, CA).  Data were extracted with the Gene Expression 
Module in GenomeStudio Software (Illumina, San Diego, CA).   
Microarray data were further analyzed, especially for differentially regulated 
pathways, using iReport (Ingenuity® Systems, www.ingenuity.com, Redwood City, 
CA).  Data from iReport only shows genes above the fold-change cutoff used for 
pathway analysis, which was 2.5 for FNAR-C1 cells and 1.5 for SKOV3 cells.  For 
genes below the 1.5-fold SKOV3 cutoff and between 1.5- and 2.5-fold change in 
FNAR-C1 cells, data was analyzed using GeneSpring GX software version 11 
(Agilent Technologies, Inc, Santa Clara, CA).  Normalization was done with all 
intensities higher than 5, log2 transformation and cross-array quartile normalization.  
For FNAR-C1 genes below the 1.5-fold cutoff, fold-change was calculated manually 
from the Agilent Feature Extraction output. 
PCR Validation of Microarray 
 PCR validation of microarray data used custom 96-well TaqMan array plates 
(Life Technologies, Grand Island, NY).  For FNAR-C1 samples, RNA came from the 
same isolation as the microarray experiment.  For SKOV3 samples, cells were sorted 
as described for the microarray.  The rest of the procedure was performed at The 
Sidney Kimmel Cancer Center Microarray Core Facility at Johns Hopkins University, 
supported by NIH grant P30 CA006973 entitled Regional Oncology Research Center.  
RNA was isolated using TRIzol isolation followed by the RNeasy Mini Kit.  cDNA 
synthesis was performed using the High Capacity RNA-to-cDNA Kit (Life 
39 
 
Technologies, Grand Island, NY).  20 ng of cDNA was added to each well of the 
custom TaqMan array plates along with TaqMan Universal PCR Master Mix (Life 
Technologies, Grand Island, NY) in a final volume of 20 µl.  Each sample was 
assayed in triplicate using three identical plates.  Data was collected using the ABI 
7500 Real-Time PCR System (Life Technologies, Grand Island, NY).  Data was 
analyzed using 7500 Fast System SDS software version 1.4 (Life Technologies, Grand 
Island, NY).  For FNAR-C1 samples, CXCL1 was used as the endogenous control.  
For SKOV3 samples, EEF1A1 was used as the endogenous control. 
Regeneration of Phenotypic Diversity Assay 
 Sorted cells were plated into vented T25 tissue culture flasks with either 
KnockOut or differentiation medium.  After four days of culture, cells were released 
from the plastic as described above and stained with Aldefluor and propidium iodide 
as described above.  Cells were analyzed on a FACSCalibur flow cytometer.  Plots 
were generated using FlowJo 8.   
In vivo Tumorigenicity 
 Cells were stained with Aldefluor and PI then sorted as described above.  
However, FNAR-C1 cells from KnockOut medium were sorted using a FACSAria 1 
or 2 and were not recovered in culture after sorting.  Sorted cells were counted and 
resuspended in RPMI such that injection of 1 ml provided the desired cell dose.  
Female Lewis rats received intraperitoneal injections with graded numbers of cells.  
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Rats were monitored weekly and euthanized when becoming moribund or when 
tumors were detected by palpating the abdomen.  Two years after the injection date, 
any remaining rats were euthanized and necropsy was performed to evaluate the 
presence of undetected cancer.  All animals were handled in accordance with the 
Johns Hopkins University Animal Care and Use guidelines.  All tumors underwent 
histological evaluation in a blinded manner to exclude any spontaneously occurring 
tumors.  Statistical significance was calculated using the Fisher’s Exact Test in 
EpiStat. 
In Vitro Drug Resistance 
 Sorted cells were plated at a density of 100 cells per well into 24-well tissue 
culture plates with six wells per condition.  FNAR-C1 cells were plated in 
differentiation medium with the following concentrations of paclitaxel (taxol): 10 nM, 
20 nM, 40 nM, and 60 nM (ALDHhigh: n=4; ALDHlow: n=5).  Taxol-resistant SKOV3 
cells were plated in differentiation medium with the following concentrations of taxol: 
100 nM (n=6), 200 nM (n=7), 400 nM (n=8), 600 nM (n=7), and 800 nM (n=3); the 
following concentrations of carboplatin (Sigma-Aldrich, St. Louis, MO): 250 ng/ml 
(n=1), 500 ng/ml (n=5), 750 ng/ml (n=5), 1 µg/ml (n=5), and 1.25 µg/ml (n=4); and 
the following concentrations of gemcitabine (Gemzar; Eli Lilly and Company, 
Indianapolis, IN): 2 nM (n=3), 3 nM (n=3), 4 nM (n=5), 5 nM (n=5), 6 nM (n=2), and 
7 nM (n=2).  Cells were continuously exposed to taxol and gemcitabine.  Cells were 
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incubated with carboplatin for 72 hours, which was then washed off and replaced with 
fresh medium.  Cells were examined weekly with a Nikon Eclipse T1-S with 4x, 10x 
and 20x objectives (Nikon Instruments Inc., Melville, NY).  Growth was defined as at 
least one colony of greater than ten cells in a well and data is presented as the 
percentage of wells that grew relative to no drug control.  Data for FNAR-C1 cells is 
from two to four weeks of growth.  Data for taxol-resistant SKOV3 cells is from two 
to three weeks of growth.  Graphs were generated using Excel 2008 for Mac.  
Statistical significance was determined using Excel 2008 for Mac to calculate the 
unpaired, 2-tailed Student’s t-test.  For drug concentrations with only two data points 
per population, the unpaired, 2-tailed Student’s t-test was calculated using GraphPad 
QuickCalcs (http://www.graphpad.com/quickcalcs/ttest1/). 
 Resistance to taxol was additionally evaluated by determining the percentage 
of ALDHhigh cells remaining after treatment.  Unsorted FNAR-C1 and SKOV3 cells 
were plated in differentiation medium with or without taxol.  For FNAR-C1, n = 3 for 
no drug and n = 4 for taxol.  Taxol doses ranged from 10 nM to 1 µM for 72 hours.  
For SKOV3, five individual assays were performed comparing SKOV3 cells to taxol-
resistant SKOV3 cells continuously cultured in the presence of 33.3 nM taxol.  Cells 
were released from plastic then stained with Aldefluor and propidium iodide as 
described above.  Data was collected on a FACSCalibur flow cytometer and analyzed 
using FlowJo 8.  Plots were generated using Excel 2008 for Mac and p-values were 











Aldefluor Defines Distinctive Populations 
 Initial observations of the FNAR-C1 rat model of ovarian cancer showed a 
small aldehyde dehydrogenase 1 high (ALDHhigh) population, as measured with the 
Aldefluor reagent.  However, continued culture in standard medium containing serum 
resulted in the loss of ALDHhigh cells.  Serum has been reported to promote the 
differentiation of stem cell populations; and for this reason, standard medium with 
serum will be referred to as differentiation medium123-126.  Despite numerous attempts, 
it was not possible to identify a culture condition that maintained both ALDHhigh and 
ALDHlow populations.  However, culturing FNAR-C1 cells in Knockout medium, 
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which is a proprietary, serum-free medium designed for the maintenance of embryonic 
stem cells in an undifferentiated state, maintained a large ALDHhigh population.   
Figure 4.1: Aldefluor Sorting 
 
Representative samples of sorting gates are shown.  All gating used DEAB as a negative control.  (A) 
FNAR-C1 cells grown in differentiation medium were sorted for the Aldefluor low population.  (B) 
FNAR-C1 cells grown in KnockOut medium were sorted for the Aldefluor high population.  (C) 
SKOV3 cells grown in differentiation medium were sorted for the Aldefluor low population.  (D) 
Taxol-resistant SKOV3 cells grown in differentiation medium were sorted for the Aldefluor low 
population.  (E) Taxol-resistant SKOV3 cells grown in KnockOut medium were sorted for the 




Therefore, in order to study the biology of both ALDHhigh and ALDHlow populations, 
two different culture conditions were used.  When stained with Aldefluor, FNAR-C1 
cells cultured in differentiation medium were predominantly ALDHlow (Figure 4.1A).  
Occasional ALDHhigh cells were seen, but they were scattered and diffuse and did not 
appear to represent a distinct population (mean = 2.05%, range = 0.23 – 9.3%).  When 
FNAR-C1 cells were grown in KnockOut medium, two clearly defined populations 
were seen, with ALDHhigh cells representing approximately half of the cells (Figure 
4.1B; mean = 56.88%, range = 15.7 – 86.5%).  It was hypothesized that ALDHhigh 
cells from KnockOut medium would represent a primitive stem-like population and 
ALDHlow cells from differentiation medium would represent a differentiated cell 
population.  Therefore, these were the two populations analyzed. 
 Like FNAR-C1 cells, SKOV3 cells cultured in differentiation medium showed 
few ALDHhigh cells (Figure 4.1C; mean = 2.12%, range = 0.18 – 6.28%).  In contrast 
to the FNAR-C1 cells, culture of SKOV3 cells in KnockOut medium did not 
substantially change the percentage of ALDHhigh cells (data not shown).  However, 
when SKOV3 cells obtained taxol-resistance, a distinct ALDHhigh population emerged 
in differentiation medium (Figure 4.1D; mean = 3.25%, range = 1.18 – 12.1%).  
Furthermore, culturing taxol-resistant SKOV3 cells in KnockOut medium resulted in a 
predominantly ALDHhigh population (Figure 4.1E; mean = 20.22, range = 10.0% to 
42.2%).  The cancer stem cell model proposes that cancer stem cells are relatively 
drug-resistant.  Therefore, it was hypothesized that ALDHhigh taxol-resistant SKOV3 
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cells from KnockOut medium might represent a stem cell-like population and 
ALDHlow SKOV3 cells from differentiation medium could represent a differentiated 
population, and so these were the principal populations studied. 
 In order to test these hypotheses, each distinct ALDH population was 
examined for commonly accepted stem cell properties.  These properties included 
nonadherent growth, quiescence, a lack of contact inhibition, size, the ability to 
regenerate the phenotypic diversity of the cell line, tumorigenicity and drug 
resistance127-133.  Finally, expression patterns consistent with a stem cell phenotype 
were analyzed. 
ALDHhigh Cells Share Morphological and Growth Characteristics With Cancer 
Stem Cells 
 Commonly accepted properties of stem cells include non-adherent growth and 
the absence of contact inhibition128.  FNAR-C1 cells grow adherently on plastic.  
Upon reaching confluency, ALDHlow cells showed substantial death, which resulted in 
large areas devoid of cells (data not shown).  ALDHhigh FNAR-C1 cells failed to 
undergo growth arrest upon achieving confluency and instead formed large three-
dimensional clusters of cells, termed nodules (Figure 4.2A).  These data suggest that 
ALDHlow cells retained contact inhibition, but ALDHhigh cells lacked contact 
inhibition.  In addition to forming nodules, a portion of ALDHhigh FNAR-C1 cells 
grew as nonadherent clusters, termed spheroids (Figure 4.2B).  Supernatant from 
ALDHlow FNAR-C1 cell cultures only showed apoptotic cells and cellular debris, 
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without any viable cell aggregates (data not shown).  ALDHhigh taxol-resistant SKOV3 
cells also displayed nonadherent growth through the formation of spheroids (Figure 
4.2C), which was not observed in ALDHlow SKOV3 cells (data not shown).  
Consistent with a stem cell phenotype, ALDHhigh cells lack contact inhibition and 
possess the capacity for nonadherent growth, which are features not observed in 
ALDHlow cells. 
Figure 4.2: Nodules and Spheroids 
Pictomicrographs showing nodules (A) and spheroid (B) in ALDHhigh FNAR-C1 cells and spheroid in 
ALDHhigh taxol-resistant SKOV3 cells (C).  For photography of ALDHhigh FNAR-C1 spheroids, the 
supernatant was moved to an empty well.  All images used a 20x phase contrast objective. 
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Figure 4.3: Cell Size 
 
Unsorted cells were stained for Aldefluor and gated on the population of interest using DEAB as a 
negative control.  The forward scatter, or size, of these cells was then displayed.  (A) FNAR-C1 cells 
are shown with ALDHhigh in red and ALDHlow in blue.  (B) SKOV3 cells are shown.  ALDHhigh taxol-
resistant SKOV3 cells are in red and ALDHlow SKOV3 cells are in blue.   
 Stem cells are typically smaller in size than their differentiated counterparts127, 
129.  Consistent with this, ALDHhigh cells from both FNAR-C1 and taxol-resistant 
SKOV3 cells were smaller than ALDHlow cells from FNAR-C1 and SKOV3 cells, 
respectively (Figure 4.3).  This smaller size is often attributed to the relative 
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quiescence of stem cells132, 133.  ALDHhigh FNAR-C1 cells had a doubling time of 32.2 
hours compared to a doubling time of 15.6 hours for ALDHlow cells (Figure 4.4A).   
Figure 4.4: Growth Curves 
 
Sorted cells were counted at 24-hour intervals.  (A) FNAR-C1 cells are shown with ALDHhigh in red 
and ALDHlow in blue.  (B) SKOV3 cells are shown.  ALDHhigh taxol-resistant SKOV3 cells are in red 
and ALDHlow SKOV3 cells are in blue.   
ALDHhigh taxol-resistant SKOV3 cells showed a similarly increased doubling time of 
39.6 hours relative to 27.0 hours in ALDHlow SKOV3 cells (Figure 4.4B).  These data 
reveal a slower growth rate in the ALDHhigh cells of both models.  This difference 
could be attributed to decreased proliferation or increased apoptosis.  Cell cycle 
analysis distinguished between these two possibilities.  ALDHhigh FNAR-C1 cells had 
fewer dividing cells than ALDHlow FNAR-C1 cells with 52.8% of ALDHhigh cells in 
the G1/G0 phase of the cell cycle versus 30.5% of ALDHlow cells (Figure 4.5A, B).  
This observation was confirmed in the SKOV3 model with 53.4% of ALDHhigh taxol-
resistant SKOV3 cells in the G1/G0 phase but only 42.2% of ALDHlow SKOV3 
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(Figure 4.5C, D).  None of the populations showed a substantial sub-G1 cell 
population that would indicate apoptosis.  Therefore, the increased doubling times of 
ALDHhigh cells are the result of decreased proliferation.   
Figure 4.5: Cell Cycle Analysis 
 
Representative cell cycle analyses using propidium iodide are shown: (A) ALDHlow FNAR-C1 cells, 
(B) ALDHhigh FNAR-C1 cells, (C) ALDHlow SKOV3 cells, (D) ALDHhigh taxol-resistant SKOV3 cells. 
Microarray data showed that the decreased proliferation of ALDHhigh cells is 
due to a block at the G1/S checkpoint.  ALDHhigh FNAR-C1 cells had downregulation 
of genes important for progression from G1 to S phase relative to ALDHlow FNAR-C1 
cells (Figure 4.6).  ALDHhigh FNAR-C1 cells showed 3.512-fold (3.922-fold by PCR) 
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downregulation of c-myc and 5.704-fold downregulation of neuregulin 1, both of 
which promote cell cycle progression134, 135.  Cyclin D1 stimulates the G1/S transition 
by complexing with cyclin dependent kinases 4 or 6 and was downregulated 2.503-
fold (2.227-fold by PCR) in ALDHhigh FNAR-C1 cells136.  Additionally, cyclin D1 
may play a role in exiting quiescence137.  Downregulation of these crucial components 
of the G1/S checkpoint in ALDHhigh FNAR-C1 cells suggests a block in cell cycle 
progression.   
Differential regulation of genes in ALDHhigh taxol-resistant SKOV3 cells 
compared to ALDHlow SKOV3 cells supports the same conclusion (Figure 4.7).  
ALDHhigh taxol-resistant SKOV3 cells showed 2.22-fold downregulation (2.532-fold 
by PCR) of cyclin dependent kinase 6, which complexes with cyclin D1 to trigger the 
G1/S transition138.  Transcription factor DP-1 (TFDP1) and ABL1 are components of 
the Rb/E2F pathway that is required for progression from G1 to S phase139-142.  TFDP1 
was downregulated 1.58-fold (1.526-fold by PCR) and ABL1 was 2.10-fold 
downregulated (3.086-fold by PCR) in ALDHhigh taxol-resistant SKOV3 cells.  In 
addition to downregulation of components of the G1/S checkpoint, ALDHhigh taxol-
resistant SKOV3 cells showed 2.28-fold overexpression (2.741-fold by PCR) of 
cyclin-dependent kinase inhibitor 1A (CDKN1A).  CDKN1A inhibits cyclin 
dependent kinases 2 and 4, which are important components of the G1/S transition143.  
Overall, ALDHhigh cells show a block at the G1/S checkpoint that results in fewer 
cycling cells and a decreased growth rate.   
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Figure 4.6: G1/S Arrest of ALDHhigh FNAR-C1 Cells  
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh FNAR-C1 cells relative to 




Figure 4.7: G1/S Arrest of ALDHhigh Taxol-Resistant SKOV3 Cells 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh taxol-resistant SKOV3 cells 




ALDHhigh Cells Are Capable of Regenerating the Phenotypic Diversity of the Cell 
Line and Are Tumorigenic In Vivo 
Cancer stem cells should reconstitute the phenotypic heterogeneity of the 
tumor, while differentiated cells would not be expected to do so128, 130-133.  ALDHlow 
FNAR-C1 (Figure 4.8C, D) and SKOV3 (Figure 4.9C, D) cells only produced 
ALDHlow cells in vitro, even when cultured in KnockOut medium that supports the 
growth of ALDHhigh cells.  Conversely, ALDHhigh FNAR-C1 (Figure 4.8A, B) and 
taxol-resistant SKOV3 (Figure 4.9A, B) cells remained ALDHhigh when cultured in 
KnockOut medium but rapidly generated ALDHlow cells in differentiation medium.  
Figure 4.8: Regeneration of Phenotypic Diversity in FNAR-C1 Cells 
 
Sorted ALDHhigh (A, B) and 
ALDHlow (C, D) FNAR-C1 
cells were plated in either 
KnockOut medium (A, C) or 
differentiation medium (B, D) 
for four days and then stained 







Accordingly, ALDHhigh, but not ALDHlow, cells regenerate the phenotypic diversity of 
the cell lines, suggesting that ALDHhigh cells represent a less differentiated phenotype 
than ALDHlow cells.   
Figure 4.9: Regeneration of Phenotypic Diversity in SKOV3 Cells 
 
Sorted ALDHhigh taxol-
resistant SKOV3 cells (A, B) 
and ALDHlow SKOV3 cells 
(C, D) were plated in either 
KnockOut medium (A, C) or 
differentiation medium (B, 
D) for four days and then 




The gold standard assay for cancer stem cells is increased in vivo 
tumorigenicity128, 131-133.  In order to test the tumorigenicity of ALDHhigh and ALDHlow 
cells, graded numbers of sorted FNAR-C1 cells were injected intraperitoneally into 
immunocompetent Lewis rats (Table 4.1).  The only rats to develop tumors were those 
receiving ALDHhigh cells.  None of the rats injected with ALDHlow cells developed 
tumors.  This provides in vivo support for the conclusion that ALDHhigh cells represent 
the tumorigenic population within FNAR-C1 cells.  
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Table 4.1: In Vivo Tumorigenicity of FNAR-C1 Cells 
 100,000 cells 1,000 cells 
ALDHhigh 3/16 (148, 177, 222) 
1/12 
(222) 
ALDHlow 0/8 0/9 
This table shows the number of rats that formed abdominal tumors out of the total number injected with 
sorted FNAR-C1 cells.  In parenthesis are days post-injection until tumors were detected. 
Figure 4.10: Drug Sensitivity 
Sorted cells were assayed for their ability to grow in increasing concentrations of drugs.  ALDHhigh cells 
grown are shown in red, and ALDHlow cells are shown in blue.  Error bars show the standard error.  (A) 
FNAR-C1 cells cultured with taxol.  (B-D) Taxol-resistant SKOV3 cells cultured in: (B) taxol, (C) 
carboplatin and (D) gemcitabine. 
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ALDHhigh Cells Display Multi-Drug Resistance 
 The cancer stem cell hypothesis proposes that cancer stem cells are more 
resistant to chemotherapy and are therefore responsible for relapse131-133.  To test the 
relative drug sensitivities of ALDHhigh and ALDHlow populations, cells were incubated 
with increasing doses of drugs and examined for growth.  ALDHhigh FNAR-C1 cells 
showed increased resistance to taxol with an IC50 of 37.4 nM versus an IC50 of 13.6 
nM for ALDHlow FNAR-C1 cells (Figure 4.10A).  The differences in drug sensitivity 
were statistically significant at the 20 nM (p = 0.015) and 40 nM (p = 0.023) doses.  
When examining the sensitivities of SKOV3 cells, it was inappropriate to compare 
taxol-resistant cells to taxol-sensitive cells.  Not only would this comparison produce 
invalid results for taxol, but also taxol-resistant cells were continuously cultured in the 
presence of taxol and would therefore be exposed to combination drug treatment when 
examining carboplatin and gemcitabine sensitivities.  For these reasons, ALDHhigh 
taxol-resistant SKOV3 cells grown in KnockOut medium were compared to ALDHlow 
taxol-resistant SKOV3 cells grown in differentiation medium.  Taxol, carboplatin and 
gemcitabine were chosen because they each have different mechanisms of action and 
resistance.  ALDHhigh taxol-resistant SKOV3 cells showed increased resistance to 
taxol with an IC50 of 427 nM compared to an IC50 of 224 nM for ALDHlow taxol-
resistant cells (Figure 4.10B).  The observed differences in sensitivity were 
statistically significant at two doses (400 nM, p=0.008; 600 nM, p=0.035).  These 
results were unexpected since both populations are grown in taxol.  ALDHhigh taxol-
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resistant SKOV3 cells also showed a trend towards increased carboplatin resistance.  
The IC50 of ALDHhigh taxol-resistant SKOV3 cells was 903 ng/ml and the IC50 of 
ALDHlow taxol-resistant SKOV3 cells was 700 ng/ml (Figure 4.10C).  These results 
approached statistical significance with a p-value of 0.08 at the 1 µg/ml carboplatin 
dose.  Finally, gemcitabine resistance was also demonstrated in ALDHhigh taxol-
resistant SKOV3 cells.  ALDHlow taxol-resistant SKOV3 cells had an IC50 of 4.3 nM, 
but ALDHhigh taxol-resistant SKOV3 cells had more than 50% growth at all doses 
tested and so the IC50 was predicted to be 7.5 nM (Figure 4.10D).  The differential 
sensitivities were statistically significant at two doses (5 nM, p = 0.0006; 6 nM, p = 
0.0128).  Therefore, ALDHhigh cells displayed resistance to chemotherapy drugs with 
different mechanisms of resistance, consistent with the multi-drug resistance of stem 
cells. 
As an additional measure of drug resistance, the change in percentage of 
ALDHhigh cells after exposure to taxol was determined.  When unsorted FNAR-C1 
cells in differentiation medium were exposed to taxol, the percentage of ALDHhigh 
cells increased from a mean of 1.1% to 4.1% (p = 0.04; Figure 4.11A).  Similarly, 
taxol-resistant SKOV3 cells in differentiation medium had an increased ALDHhigh 
population (mean = 4.1%) compared to taxol-sensitive SKOV3 cells cultured in 
differentiation medium (mean = 0.4%, p = 0.024; Figure 4.11B).  This suggests that 
drug treatment enriches for ALDHhigh cells, likely due to selective elimination of 
ALDHlow cells, and that this occurs even under conditions that do not support the 
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growth of stem cells.  The increased resistance of ALDHhigh cells was associated with 
upregulation of the multi-drug resistance 1 (MDR1) gene (ABCB1 in humans and 
ABCB1B in rats), which is an ATP-binding cassette transporter that functions in drug 
efflux and is a primary mechanism of taxol resistance144.  ALDHhigh FNAR-C1 cells 
displayed 16.797-fold upregulation (24.603-fold by PCR) of ABCB1B compared to 
ALDHlow FNAR-C1 cells (Table 4.2, pg. 98).  ABCB1 was 3.743-fold upregulated 
(374.276-fold by PCR) in ALDHhigh taxol-resistant SKOV3 cells compared to 
ALDHlow SKOV3 cells (Table 4.2, pg. 98).  Therefore, increased expression of the 
MDR1 gene may contribute to taxol resistance in ALDHhigh cells and their enrichment 
after taxol treatment.  However, MDR1 plays no role in gemcitabine or carboplatin 
resistance. 
Figure 4.11: Percentage of ALDHhigh Cells After Taxol Treatment 
 
Unsorted FNAR-C1 (A) and SKOV3 (B) cells were cultured in differentiation medium with or without 
taxol.  The percentage of ALDHhigh cells was then measured.   
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ALDHhigh Cells’ Gene Expression Is Consistent With a Stem Cell Phenotype 
 Microarray analysis examined gene expression patterns consistent with a stem 
cell phenotype.  The embryonic stem cell pluripotency pathway in FNAR-C1 cells is 
shown in Figure 4.12 (pg. 62).  Data are presented as ALDHhigh FNAR-C1 cells versus 
ALDHlow FNAR-C1 cells.  ALDHhigh FNAR-C1 cells showed upregulation of 
WNT2B (92.03-fold by microarray, 581.598-fold by PCR), WNT4 (10.745-fold by 
microarray, 18.296-fold by PCR) and WNT11 (8.719-fold by microarray, 15.722-fold 
by PCR)145.  Each of these WNT genes has been shown to play important roles in stem 
cells.  Embryonic stem cells express WNT2B146.  Additionally, WNT2B is associated 
with metastasis and chemoresistance in ovarian cancer147.  WNT4 is important in 
progenitor cell expansion148, 149.  Finally, WNT11 has been shown to maintain 
proliferating stem cells in the presence of retinoic acid150.  Also in the Wnt/β-catenin 
pathway is the TCF/LEF complex that is important for stem cell self-renewal151, 152.  
ALDHhigh FNAR-C1 cells exhibited 3.225-fold upregulation (88.626-fold by PCR) of 
LEF1 and 4.192-fold upregulation (6.754-fold by PCR) of TCF7L1.   
In addition to WNT family members, other stem cell associated genes were 
upregulated in ALDHhigh FNAR-C1 cells.  Platelet-derived growth factor β, which is 
involved in stem cell maintenance, was upregulated 3.192-fold (12.254-fold by PCR) 
in ALDHhigh FNAR-C1 cells153, 154.  Brain-derived neurotrophic factor was 5.886-fold 
(6.567-fold by PCR) upregulated in ALDHhigh FNAR-C1 cells and can induce stem 
cell proliferation155.  Stem cells express high levels of neurotrophin 3, and ALDHhigh 
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FNAR-C1 cells demonstrated 3.18-fold upregulation156.  Fibroblast growth factor 
receptors (FGFR) 1 and 2 are required for the maintenance of a diverse array of stem 
cells157, 158.  FGFR1 was 3.736-fold upregulated (24.101-fold by PCR) and FGFR2 
was 22.621-fold upregulated (33.065-fold by PCR) in ALDHhigh FNAR-C1 cells.  
Bone morphogenetic protein 7, which was 4.44-fold upregulated (3.329-fold by PCR) 
in ALDHhigh FNAR-C1 cells, is important for the survival and proliferation of 
progenitor cells159.  Accordingly, ALDHhigh FNAR-C1 cells showed upregulation of 
numerous genes that serve crucial functions in the maintenance, self-renewal and 
proliferation of stem cells. 
 The embryonic stem cell pluripotency pathway in Figure 4.13 (pg. 63) displays 
genes differentially regulated in ALDHhigh taxol-resistant SKOV3 cells relative to 
ALDHlow SKOV3 cells.  Despite some dissimilarity with ALDHhigh FNAR-C1 cells, 
ALDHhigh taxol-resistant SKOV3 cells also demonstrated an expression pattern 
consistent with a stem cell phenotype.  ALDHhigh taxol-resistant SKOV3 cells showed 
1.58-fold upregulation of the regulatory subunit of phosphoinositide-3-kinase, which 
is important in breast cancer stem cells160.  SMAD3 signaling maintains stem cell 
pluripotency and was upregulated 1.66-fold in ALDHhigh taxol-resistant SKOV3 
cells161.  Self-renewal of stem cells is strongly influenced by bone morphogenetic 
protein 4 (BMP4)162.  Accordingly, ALDHhigh taxol-resistant SKOV3 cells 
demonstrated 5.67-fold upregulation of BMP4.  Bone morphogenetic protein 5 has the 
capacity to increase the number of stem cells and ALDHhigh taxol-resistant SKOV3 
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cells displayed 3.01-fold (117.407-fold by PCR) upregulation versus ALDHlow 
SKOV3 cells163.  In addition to upregulation of stem cell associated genes, ALDHhigh 
taxol-resistant SKOV3 cells showed downregulation of a gene associated with 
differentiation: bone morphogenetic protein 1 (1.55-fold downregulation)164.  Similar 
to ALDHhigh FNAR-C1 cells, ALDHhigh taxol-resistant SKOV3 cells exhibited 
upregulation of genes that control vital properties of stem cells and downregulation of 
a gene involved in differentiation. 
 ALDHhigh cells additionally showed differential regulation of genes in the 
OCT4 pathway consistent with a stem cell phenotype.  Figure 4.14 (pg. 64) shows 
ALDHhigh FNAR-C1 cells compared to ALDHlow FNAR-C1 cells.  NR2F1 was 2.625-
fold upregulated in ALDHhigh FNAR-C1 cells and has been reported to induce 
quiescence165.  CDX2 induces differentiation and was downregulated 12.968-fold in 
ALDHhigh FNAR-C1 cells166.  Therefore, differential expression of genes in the OCT4 
pathway suggests that ALDHhigh FNAR-C1 cells exhibit a more primitive phenotype 
than their ALDHlow counterparts.  Figure 4.15 (pg. 65) presents the OCT4 pathway in 
ALDHhigh taxol-resistant SKOV3 calls relative to ALDHlow SKOV3 cells.  ALDHhigh 
taxol-resistant SKOV3 cells displayed 3.74-fold upregulation (3.298-fold by PCR) of 
the downstream effector secreted phosphoprotein 1, which is highly expressed in stem 
and progenitor cells167.  Observations in both models suggest the OCT4 pathway plays 
a role in the maintenance of a stem cell phenotype in ALDHhigh cells. 
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Figure 4.12: FNAR-C1 Embryonic Stem Cell Pluripotency 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh FNAR-C1 cells relative to 





Figure 4.13: SKOV3 Embryonic Stem Cell Pluripotency 
Pathway analysis of microarray data.  Data is presented as ALDHhigh taxol-resistant SKOV3 cells 




Figure 4.14: FNAR-C1 Oct4 in Mammalian Embryonic Stem Cell Pluripotency 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh FNAR-C1 cells relative to 





Figure 4.15: SKOV3 Oct4 in Mammalian Embryonic Stem Cell Pluripotency 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh taxol-resistant SKOV3 cells 





ALDHhigh Cells Represent a Biologically Distinct Population 
 Data presented thus far show that ALDHhigh cells represent a stem cell-like 
population within ovarian cancer.  Therefore, studying gene expression differences in 
these cells should reveal biological properties of ovarian cancer stem cells.  The 
FNAR-C1 and SKOV3 models represent different ovarian cancer subtypes.  By 
examining microarray data for those features that are consistently differentially 
regulated in the ALDHhigh cells of both models, it may be possible to identify 
properties of ovarian cancer stem cells that would be representative of all patients, 
rather than those with a specific subtype. 
 For microarray analysis, cells were isolated based on different levels of 
Aldefluor staining.  In order to validate the Aldefluor staining patterns in isolated cells 
with aldehyde dehydrogenase 1 (ALDH1) expression, the expression levels of ALDH1 
family members were examined.  The enzymes of the ALDH1 family are also known 
as retinaldehyde dehydrogenases.  Although the precise function of ALDH1 enzymes 
in stem-cell biology is unclear, the major biological function of the ALDH1 family 
appears to be the biosynthesis of retinoic acid, the active metabolite of vitamin A 
(retinol).  ALDH1 catalyzes the final step of this process, the oxidation of 
retinaldehyde to retinoic acid168.  There are three known members of the family, 
ALDH1A1, A2, and A3, with somewhat redundant expression and function.  In 
ALDHhigh FNAR-C1 cells, there was 86.522-fold upregulation (325.761-fold by PCR) 
of ALDH1A2 relative to ALDHlow FNAR-C1 cells (Table 4.2, pg. 98).  ALDHhigh 
67 
 
taxol-resistant SKOV3 cells expressed ALDH1A1 at a 23.699-fold greater level 
(44.494-fold by PCR) than ALDHlow SKOV3 cells (Table 4.2, pg. 98).  Not only does 
this confirm that Aldefluor high cells have the expected increased expression of 
ALDH1, it suggests that there may be species differences with regard to specific 
isoenzyme expression. 
 Tight junctions form barriers that prevent diffusion of molecules between 
epithelial cells.  Additionally, signaling through tight junction proteins regulates 
cellular behavior.  Both models exhibited upregulation of tight junction genes in 
ALDHhigh cells suggesting a role for this pathway in ovarian cancer stem cells.  Figure 
4.16 presents the expression of tight junction genes in ALDHhigh FNAR-C1 cells 
relative to ALDHlow FNAR-C1 cells, and Figure 4.17 represents ALDHhigh taxol-
resistant SKOV3 cells compared to ALDHlow SKOV3 cells.  Claudin genes, the 
primary proteins that form tight junctions and regulate their permeability, were 
upregulated in ALDHhigh cells (FNAR-C1: claudin 23; SKOV3: claudins 1 and 3, 
confirmed by PCR).  A second class of tight junction genes, junctional adhesion 
molecules (JAM), exhibited differential regulation in ALDHhigh FNAR-C1 cells with 
2.96-fold upregulation of JAM3 (4.882-fold by PCR).  Both models also showed 
upregulation of multiple intracellular signaling components.  Although it is clear that 
ALDHhigh cells have the capacity for increased tight junction formation and 
intracellular signaling, the strength of the barriers formed is less certain.   
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Figure 4.16: FNAR-C1 Tight Junction Signaling 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh FNAR-C1 cells relative to 





Figure 4.17: SKOV3 Tight Junction Signaling 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh taxol-resistant SKOV3 cells 





Not present in the pathway analysis is CXADR, which is important for tight junction 
integrity and was upregulated in ALDHhigh cells of both models (Table 4.2, pg. 98)169, 
170.  This would suggest that ALDHhigh cells form robust barriers.  However, ALDHhigh 
cells also displayed upregulation of several genes that increase tight junction 
permeability, including protein phosphatase 2A (PP2A) family members in both 
models and myosin light chain kinase in FNAR-C1 cells (MYLK: 89.956-fold by 
PCR)171, 172.  While the integrity of tight junctions formed by ALDHhigh cells is 
uncertain, it is apparent that tight junction signaling may play an important role in 
ALDHhigh cells.  Additionally, the tendency of ALDHhigh cells to grow as clusters and 
form spheroids may be due to increased formation of tight junctions. 
 Differential gene expression suggests that ALDHhigh cells may represent tumor 
initiating cells.  Tumor suppressors in the kruppel-like factor, S100 calcium binding 
protein and epithelial membrane protein families were downregulated in ALDHhigh 
cells (Table 4.4, pg. 102)173-178.  ALDHhigh cells also appear to have an increased 
capacity for invasion.  ALDHhigh FNAR-C1 cells displayed upregulation of bone 
morphogenetic protein 7, cadherin 11, protein tyrosine kinase 7, matrix 
metallopeptidase 2 and matrix metallopeptidase 14 (Table 4.4, pg. 102)179-182.  
Different members of the same gene families were upregulated in ALDHhigh taxol-
resistant SKOV3 cells, comprising bone morphogenetic protein 4, protein tyrosine 
kinase 2 and matrix metallopeptidase 7 (Table 4.4, pg. 102)183-185.  These genes have 
been shown to induce migration and invasion, so upregulation implies that ALDHhigh 
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cells represent the invasive population of tumor cells.  Further supporting this 
conclusion is downregulation of inhibitors of extracellular matrix degradation.  
SERPINB2 was downregulated in ALDHhigh FNAR-C1 cells, as was SERPINE1 in 
ALDHhigh taxol-resistant SKOV3 cells (Table 4.4, pg. 103)186, 187.  Not only do 
ALDHhigh cells have an increased capacity for invasion, but this process is aided by 
reduced deposition of the extracellular matrix.  Collagen components of the basement 
membrane exhibited reduced expression in ALDHhigh cells (Table 4.4, pg. 103)188-191.  
Additionally, the transmembrane collagen COL17A1 was downregulated in ALDHhigh 
cells of both models (Table 4.3, pg. 100)192.  The formation of mature collagen fibers 
requires processing of procollagen molecules.  ALDHhigh cells showed downregulation 
of PCOLCE2, which binds to procollagen to enhance its cleavage, and downregulation 
of P4HA2, which is a component of the key collagen synthesis enzyme prolyl 4-
hydroxylase (Table 4.3, pg. 100)193, 194.  In addition to reduced collagen expression 
and processing, laminin components of the basement membrane were also 
downregulated in ALDHhigh cells, including LAMB3 and LAMC2 (Table 4.3, pg. 
100)195.  The apparent reduced extracellular matrix deposition seen in ALDHhigh cells 
would facilitate invasion by diminishing the amount of extracellular matrix 
degradation required.  These observations suggest that ALDHhigh cells display an 




Expression patterns in both models suggest decreased coagulation in ALDHhigh 
cells.  Figure 4.18 displays the expression of coagulation genes in ALDHhigh FNAR-
C1 cells compared to ALDHlow FNAR-C1 cells, and Figure 4.19 shows ALDHhigh 
taxol-resistant SKOV3 cells relative to ALDHlow SKOV3 cells.  In ALDHhigh cells, 
coagulation was primarily inhibited via upregulation of tissue factor pathway inhibitor 
(TFPI), which blocks the extrinsic pathway of the coagulation cascade (Table 4.2, pg. 
98)196.  Additionally, ALDHhigh taxol-resistant SKOV3 cells exhibited 1.87-fold 
downregulation of fibrin, further reducing clot formation197.  Inhibition of the extrinsic 
coagulation pathway has intriguing implications in ovarian cancer.  The extrinsic 
pathway is activated by tissue damage, which is likely to result if cancer cells disrupt 
the integrity of blood vessels during invasion198.  If coagulation were allowed to 
proceed under these circumstances, it would sequester migrating cancer cells.  
Therefore, inhibition of the extrinsic coagulation pathway could permit widespread 
cancer dissemination.  The inhibited coagulation in ALDHhigh cells along with the 
increased capacity for invasion further supports the conclusion that ALDHhigh cells 
represent the population that initiates metastasis. 
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Figure 4.18: FNAR-C1 Coagulation System 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh FNAR-C1 cells relative to 




Figure 4.19: SKOV3 Coagulation System 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh taxol-resistant SKOV3 cells 




Inconsistent Expression of Previously Reported Ovarian Cancer Stem Cell 
Markers in ALDHhigh Cells 
In addition to ALDH1, several different markers have been proposed to enrich 
for ovarian cancer stem cells, including CD24, CD44, KIT and CD133.  However, 
most studies only examined one marker.  Because of this, it is not known if these 
markers identify the same cell population.  Gene expression analysis of ALDHhigh and 
ALDHlow cells allowed for examination of alternative ovarian cancer stem cell makers 
to determine coexpression.  By assessing two distinct ovarian cancer subtypes, those 
makers with consistent coexpression could be identified. 
 While CD24 has been proposed as an ovarian cancer stem cell marker, 
disagreements exist concerning whether ovarian cancer stem cells express it to a 
greater or lesser degree than differentiated cells46, 59.  ALDHhigh taxol-resistant SKOV3 
cells exhibited substantial downregulation of CD24 relative to ALDHlow SKOV3 cells 
(Table 4.5, pg. 108).  ALDHhigh FNAR-C1 cells also showed downregulation of 
CD24, but to a lesser degree than in SKOV3 cells (Table 4.5, pg. 108).  Therefore, 
ovarian cancer stem cells may express lower levels of CD24 than differentiated cells.  
However, all populations expressed considerable levels of CD24, potentially limiting 
its usefulness as a marker for isolation.   
 High expression of CD44 has been reported to enrich for ovarian cancer stem 
cells28, 29.  In opposition to these reports, ALDHhigh FNAR-C1 cells exhibited 
substantial downregulation of CD44 relative to ALDHlow FNAR-C1 cells (Table 4.5, 
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pg. 108).  However, there was no difference in CD44 expression between ALDHhigh 
taxol-resistant SKOV3 cells and ALDHlow SKOV3 cells (Table 4.5, pg. 108).  
Additionally, both SKOV3 populations showed very high levels of expression.  While 
these results contradict previous reports using CD44 positivity to isolate ovarian 
cancer stem cells, there are reports of tumorigenic ovarian cancer cells lacking CD44 
expression36, 37.  The data presented here indicates variable expression of CD44 in 
ALDHhigh cells, which challenges the use of CD44 as a universal ovarian cancer stem 
cell marker. 
 Published reports of ovarian cancer stem cells demonstrate stark variability in 
KIT expression, which is reflected in this study25, 29, 34, 61.  In FNAR-C1 cells, KIT 
expression was too low for differences to be reliably detected by microarray.  PCR 
data showed that KIT expression was largely confined to the ALDHhigh population 
(Table 4.5, pg. 108).  ALDHhigh taxol-resistant SKOV3 cells exhibited the opposite 
pattern with expression of KIT only reliably detected in ALDHlow SKOV3 cells (Table 
4.5, pg. 108).  In conjunction with previously published results, these findings indicate 
dynamic expression of KIT in ovarian cancer stem cells. 
 Ovarian cancer stem cells have been isolated based on CD133 positivity49, 55.  
CD133 expression was too low to be reliably detected in FNAR-C1 cells using 
microarray analysis.  PCR analysis showed possible downregulation of CD133 in 
ALDHhigh FNAR-C1 cells (Table 4.5, pg. 108).  CD133 was undetectable in the 
ALDHhigh population but appeared to be expressed at a very low level in the ALDHlow 
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fraction.  In ALDHhigh taxol-resistant SKOV3 and ALDHlow SKOV3 cells, CD133 
expression was too low for reliable detection by either assay (Table 4.5, pg. 108).  
Therefore, ALDHhigh cells do not express higher levels of CD133.  Furthermore, none 
of the tested populations displayed robust expression of CD133.  This is consistent 
with findings of CD133 expression in only 30% of ovarian tumors, which limits the 
potential of CD133 for isolation of ovarian cancer stem cells57. 
Multiple markers of ovarian cancer stem cells have been proposed and each 
marker has been shown to identify a population of ovarian cancer cells with stem cell 
properties.  Published studies have generally only examined one marker.  This does 
not allow for comparison of the different markers, and so it is not known if these 
markers identify the same cell population.  The data presented here suggests overlap 
between cells with high expression of ALDH1 and decreased expression of CD24.  
The remaining markers (CD44, KIT and CD133) do not exhibit consistent differential 
expression in ALDHhigh cells indicating that these markers identify different cell 
populations than ALDH1. 
No Consistent Differential Regulation of Hormone Receptors in ALDHhigh Cells 
 Steroid hormones and their receptors have been implicated in the pathogenesis 
of ovarian cancer, and hormone receptor status serves as a prognostic indicator.  
Therefore, it is important to evaluate differential expression of hormone receptors in 
ovarian cancer stem cells.  Expression of estrogen receptor α (ESR1) was too low to 
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reliably detect differences by microarray.  PCR data indicated downregulation of 
ESR1 in ALDHhigh FNAR-C1 cells compared to ALDHlow FNAR-C1 cells (Table 4.5, 
pg. 108).  ALDHhigh taxol-resistant SKOV3 cells, however, exhibited upregulation of 
ESR1 relative to ALDHlow SKOV3 cells (Table 4.5, pg. 108).  In FNAR-C1 cells, 
progesterone receptor (PGR) expression appeared to be predominantly confined to 
ALDHhigh cells (Table 4.5, pg. 108).  In SKOV3 cells, the opposite pattern was seen.  
ALDHhigh taxol-resistant SKOV3 cells did not express detectable levels of PGR, but 
very low levels of expression were detected in ALDHlow SKOV3 cells (Table 4.5, pg. 
108).  In all populations tested, expression of androgen receptor was too low to 
reliably detect differences.  Overall, no consistent differences in hormone receptor 
expression were found between ALDHhigh and ALDHlow cells, suggesting no reliable 
association exists between hormone receptor expression and ovarian cancer stem cells. 
Gonadotropins have been proposed to play a role in the progression of ovarian 
cancer, and therapies targeting gonadotropin receptors have been tested.  Therefore, 
the expression of gonadotropin receptors in ovarian cancer stem cells may be relevant 
to therapeutics.  Modest expression of follicle stimulating hormone receptor (FSHR) 
was measured in ALDHhigh and ALDHlow FNAR-C1 cells by microarray (Table 4.5, 
pg. 108).  FSHR could not be detected by PCR, but the clear expression by microarray 
suggests that this is likely a technical rather than biological phenomenon (Table 4.5, 
pg. 108).  ALDHhigh taxol-resistant SKOV3 and ALDHlow SKOV3 cells did not appear 
to express FSHR when measured by microarray (Table 4.5, pg. 108).  Luteinizing 
79 
 
hormone/choriogonadotropin receptor (LHCGR) did not appear to be expressed in any 
population tested (Table 4.5, pg. 108).  Overall, gonadotropin receptors do not appear 
to be consistently expressed in ALDHhigh cells, which could have important 
implications for gonadotropin receptor targeted therapies. 
 Although her-2/neu and CA125 are not hormone receptors, their prognostic 
importance in ovarian cancer necessitates evaluation of expression levels in ovarian 
cancer stem cells.  High levels of her-2/neu (ERBB2) expression were detected in all 
populations tested, but no reliable differences were found between ALDHhigh and 
ALDHlow cells (Table 4.5, pg. 108).  Therefore, ERBB2 does not appear to be 
consistently differentially regulated in ALDHhigh ovarian cancer cells.  Modest 
expression of CA125 (MUC16) was detected in all populations studied.  ALDHhigh 
FNAR-C1 cells showed upregulation of MUC16 relative to ALDHlow FNAR-C1 cells 
(Table 4.5, pg. 108).  In contrast, no differences were seen between ALDHhigh taxol-
resistant SKOV3 cells and ALDHlow SKOV3 cells (Table 4.5, pg. 108).  This indicates 
consistent expression of MUC16 in ovarian cancer stem cells. 
Upregulation of MDR1, But Not Other ABC Transporters, in ALDHhigh Cells 
 Increased expression of ATP-binding cassette (ABC) transporters leads to 
resistance to a wide array of drugs, possibly causing multi-drug resistance in stem 
cells199.  The only ABC transporter that showed strong upregulation in ALDHhigh cells 
of both models was the multidrug resistance protein 1 (MDR1), which is designated 
ABCB1 in humans and ABCB1B in rats (Table 4.2, pg. 98).  Resistance to taxol 
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primarily results from increased expression of MDR1.  Because the human model 
compares taxol-resistant to taxol-sensitive SKOV3 cells, upregulation of MDR1 may 
be associated with the acquisition of taxol resistance.  Members of the multidrug 
resistance-associated protein subfamily (ABCC_) also induce multi-drug resistance.  
In ALDHhigh and ALDHlow FNAR-C1 cells, high expression of ABCC1 was seen with 
the highest expression in ALDHlow cells (Table 4.5, pg. 108).  In contrast, similar 
levels of modest ABCC1 expression were detected in ALDHhigh taxol-resistant 
SKOV3 cells and ALDHlow SKOV3 cells (Table 4.5, pg. 108).  ABCC3 was 
upregulated in ALDHhigh taxol-resistant SKOV3 cells but was still highly expressed in 
both populations (Table 4.5, pg. 108).  Conversely, both populations of FNAR-C1 
cells showed similarly low levels of ABCC3 expression (Table 4.5, pg. 108).  Side 
population is one proposed method to enrich for stem cells and is commonly attributed 
to ABCG2 expression38, 39.  Similarly high levels of ABCG2 expression were seen in 
ALDHhigh and ALDHlow FNAR-C1 cells with no apparent difference between the two 
populations (Table 4.5, pg. 108).  However, ABCG2 was found to be upregulated in 
ALDHhigh taxol-resistant SKOV3 cells relative to ALDHlow SKOV3 cells (Table 4.5, 
pg. 108).  Although expression of ABCG2 varied in ALDHlow cells, consistent 
expression was seen in the ALDHhigh population.  No other ABC transporters 
associated with a stem cell phenotype or drug resistance were differentially regulated 
in either model.  Overall, these data suggest that expression of ABC transporters may 
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not be consistently differentially regulated between ovarian cancer stem cells and their 
differentiated counterparts. 
Telomerase Is Not Upregulated in ALDHhigh Cells 
 Cells that undergo repeated cell division must maintain telomere length.  
Accordingly, elevated telomerase activity has been reported in a variety of cancer stem 
cells, and so expression of telomerase genes was examined200-202.  Both ALDHhigh and 
ALDHlow populations of FNAR-C1 cells showed comparably modest levels of TERC 
expression (Table 4.5, pg. 108).  Modest expression of TERC was also detected in 
ALDHhigh taxol-resistant SKOV3 and ALDHlow SKOV3 cells, but with slight 
upregulation in the ALDHhigh population (Table 4.5, pg. 108).  Relative to expression 
levels of TERC, FNAR-C1 cells expressed higher levels of TERT, but SKOV3 cells 
expressed lower levels of TERT.  TERT was not differentially expressed in ALDHhigh 
FNAR-C1 compared to ALDHlow FNAR-C1 cells (Table 4.5, pg. 108).  In contrast, 
TERT was downregulated in ALDHhigh taxol-resistant SKOV3 cells versus ALDHlow 
SKOV3 cells (Table 4.5, pg. 108).  All populations tested exhibited very high 
expression of DKC1 with possible slight downregulation in ALDHhigh cells compared 
to ALDHlow cells in both models (Table 4.5, pg. 108).  FNAR-C1 cells expressed high 
levels of TEP1 with no apparent differences between ALDHhigh and ALDHlow 
populations (Table 4.5, pg. 108).  However, SKOV3 cells showed low expression of 
TEP1 with downregulation in ALDHhigh taxol-resistant SKOV3 cells.  Overall, no 
consistent upregulation of telomerase genes was observed in ALDHhigh cells.  
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Additionally, the specific telomerase genes displayed highly variable levels of 
expression within the same populations.  This suggests that telomerase activity is not 
responsible for telomere maintenance in these models. 
Developmental Pathways Are Not Consistently Active In ALDHhigh Cells 
 Developmental pathways not only regulate embryonic development, but 
various reports suggest that they also play an important role in ovarian cancer stem 
cells.  Proliferation of ovarian cancer stem cells depends on NFκB signaling203.  The 
Wnt/β-catenin pathway regulates tumor-initiating capacity and chemoresistance in 
ovarian cancer stem cells204, 205.  Ovarian cancer stem cell survival involves Notch 
signaling35.  Although no data specific to ovarian cancer stem cells exists at this time, 
Hedgehog signaling has been reported in cancer stem cells and chemoresistant ovarian 
cancer cells54, 206.  Because of the reported importance of developmental pathways in 
ovarian cancer stem cells, gene expression patterns for the NFκB, Wnt/β-catenin, 
Notch and Hedgehog pathways were examined in ALDHhigh cells. 
 Analysis of the NFκB pathway revealed upregulation of many genes in 
ALDHhigh FNAR-C1 cells relative to ALDHlow FNAR-C1 cells (Figure 4.20).  
Receptors often serve as a primary level of pathway regulation.  Accordingly, 
ALDHhigh cells expressed higher levels of several NFκB pathway receptors.  Toll-like 
receptor 3, which activates the NFκB pathway in response to double-stranded RNA, 
showed 2.51-fold upregulation207.  Activating growth factor receptors also exhibited 
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upregulation, including: fibroblast growth factor receptors 1 and 2 (FGFR1: 3.82-fold, 
24.101-fold by PCR; FGFR2: 22.67-fold, 33.065-fold by PCR), fms-related tyrosine 
kinase 1 (3.13-fold), and growth hormone receptor (4.65-fold)208-210.  In addition to 
receptors, intracellular kinases regulate pathway activity.  ALDHhigh cells showed 
4.18-fold upregulation of mitogen-activated protein kinase kinase 6, which triggers a 
signaling cascade that activates NFκB211.  Finally, ALDHhigh cells displayed 2.99-fold 
(3.553-fold by PCR) upregulation of a component of the NFκB complex, RELA212.  
Although not differentially regulated, both ALDHhigh and ALDHlow FNAR-C1 cells 
strongly expressed NFκB.  Overall, upregulation of receptors, an activating kinase and 
a component of the NFκB complex indicates increased NFκB pathway activity in 
ALDHhigh FNAR-C1 cells.   
Conversely, ALDHhigh taxol-resistant SKOV3 cells showed downregulation of 
the NFκB pathway compared to ALDHlow SKOV3 cells (Figure 4.21).  Differential 
expression of receptors served as the primary level of regulation.  TNFRSF11B and 
interleukin 1 receptor type II (IL1R2) are decoy receptors that lack intracellular 
signaling motifs, thereby inhibiting pathway activation213, 214.  ALDHhigh cells 
displayed 2.09-fold upregulation of TNFRSF11B and 2.40-fold upregulation of 
IL1R2.  Furthermore, the activating receptor TGFBR2 exhibited 2.69-fold (12.987-
fold by PCR) downregulation215.  The observed downregulation of a signaling receptor 
and upregulation of decoy receptors suggests reduced activity of the NFκB pathway in 
ALDHhigh taxol-resistant SKOV3 cells. 
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Figure 4.20: FNAR-C1 NFκB Signaling 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh FNAR-C1 cells relative to 




Figure 4.21: SKOV3 NFκB Signaling 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh taxol-resistant SKOV3 cells 






The Wnt/β-catenin pathway exhibited substantial differential regulation in 
ALDHhigh FNAR-C1 cells relative to ALDHlow FNAR-C1 cells (Figure 4.22).  
ALDHhigh cells showed upregulation of multiple WNT genes, including: WNT2B 
(93.69-fold, 581.598-fold by PCR), WNT4 (10.79-fold, 18.296-fold by PCR), 
WNT10A (2.56-fold), and WNT11 (10.75-fold, 15.722-fold by PCR).  Although 
secreted WNT proteins can act in an autocrine or paracrine manner, upregulation of 
intracellular pathway components in ALDHhigh cells suggests increased Wnt/β-catenin 
activity in this population.  MARK2 promotes nuclear translocation of β-catenin and 
exhibited 4.29-fold upregulation (5.212-fold by PCR) in ALDHhigh cells216.  However, 
observation of nuclear β-catenin in unsorted cells cultured in differentiation medium 
suggests that nuclear β-catenin may not be restricted to the ALDHhigh population 
(Figure 2.4).  Transcription of β-catenin target genes requires the LEF/TCF complex 
in addition to nuclear β-catenin217.  ALDHhigh cells displayed 3.31-fold upregulation 
(88.626-fold by PCR) of LEF1 and 4.20-fold upregulation (6.754-fold by PCR) of 
TCF7L1.  Additionally, ALDHlow cells did not express detectable levels of LEF1.  
This implies that transcription of β-catenin target genes can only take place in 
ALDHhigh cells.  Therefore, ALDHhigh FNAR-C1 cells have increased Wnt/β-catenin 




Figure 4.22: FNAR-C1 Wnt/β-Catenin Signaling 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh FNAR-C1 cells relative to 





Figure 4.23: SKOV3 Wnt/β-Catenin Signaling 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh taxol-resistant SKOV3 cells 




 In contrast, ALDHhigh taxol-resistant SKOV3 cells showed downregulation of 
the Wnt/β-catenin pathway relative to ALDHlow SKOV3 cells (Figure 4.23).  
ALDHhigh cells exhibited 1.63-fold downregulation (2.519-fold by PCR) of β-catenin 
(CTNNB1).  In addition to downregulation of this crucial transcriptional coregulator, 
frizzled family receptor 2 (FZD2), the predominant frizzled receptor expressed in 
these cells, displayed 1.62-fold downregulation in ALDHhigh cells.  Additional 
reduction of pathway activity in ALDHhigh cells was suggested by 2.67-fold 
upregulation of the inhibitor SOX17 and 1.60-fold downregulation of the activator 
APPL2218, 219.  Based on downregulation of the preponderant receptor, downregulation 
of β-catenin, and differential regulation of genes that modulate pathway activity, the 
Wnt/β-catenin pathway appears to be less active in ALDHhigh taxol-resistant SKOV3 
cells than in ALDHlow SKOV3 cells. 
Although few genes of the Notch pathway were differentially regulated in 
ALDHhigh FNAR-C1 cells compared to ALDHlow FNAR-C1 cells, those that were 
differentially expressed serve as important regulators of pathway activity (Figure 
4.24).  ALDHhigh cells exhibited downregulation of the Notch ligands jagged 1 (JAG1, 
1.85-fold) and jagged 2 (JAG2, 6.14-fold), which would primarily impact signaling in 
adjacent cells.  However, the endocytosis of Notch ligands bound to cleaved Notch 
also alters signaling in the ligand-expressing cell220.  Manic fringe (MFNG) inhibits 
jagged 1 activation of Notch signaling and showed 3.66-fold upregulation in ALDHhigh 
cells221.  Overall, ALDHhigh FNAR-C1 cells displayed differential regulation of genes 
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that suggests reduced Notch signaling, but this effect may not be limited to the 
ALDHhigh population. 
Differential regulation of Notch pathway genes in ALDHhigh taxol-resistant 
SKOV3 cells versus ALDHlow SKOV3 cells suggests altered Notch signaling (Figure 
4.25).  The only intracellular pathway component to exhibit differential regulation was 
nicastrin (NCSTN), which is a component of the γ-secretase complex.  γ-Secretase 
cleaves the intracellular domain of Notch to permit signaling222.  Although nicastrin 
showed 1.52-fold downregulation in ALDHhigh cells, the gene was still highly 
expressed in both ALDHhigh and ALDHlow cells, and the other known components of 
γ-secretase were expressed at similar levels in both populations.  Therefore, γ-
secretase is likely active in both populations.  Altered Notch signaling appeared to be 
primarily due to 2.12-fold downregulation of lunatic fringe (LFNG) in ALDHhigh cells.  
Lunatic fringe inhibits jagged 1 signaling through Notch 1, and so downregulation 
would increase Notch signaling223.  Differential regulation of genes in ALDHhigh taxol-
resistant SKOV3 cells suggests increased Notch signaling, however this altered 
signaling may impact other cell populations as well. 
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Figure 4.24: FNAR-C1 Notch Signaling 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh FNAR-C1 cells relative to 




Figure 4.25: SKOV3 Notch Signaling 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh taxol-resistant SKOV3 cells 




The data presented here indicates inconsistent developmental pathway activity 
in ovarian cancer stem cells from different sources.  ALDHhigh FNAR-C1 cells 
displayed upregulation of the NFκB and Wnt/β-catenin pathways but downregulation 
of Notch signaling.  ALDHhigh taxol-resistant SKOV3 cells demonstrated the opposite 
pattern with upregulated Notch signaling but downregulated NFκB and Wnt/β-catenin 
pathways.  The only consistency between the two models was that neither model 
exhibited differential regulation of the Hedgehog pathway.  While this data indicates a 
role for developmental pathways in ovarian cancer stem cells, their significance is not 
consistent. 
Potential Therapeutic Targets to Eliminate ALDHhigh Cells 
 The primary purpose of studying ovarian cancer stem cells was to identify 
potential therapies.  If the cancer stem cell hypothesis is accurate, eliminating ovarian 
cancer stem cells should lead to durable remission for patients.  Microarray data 
identified gene expression profiles in ALDHhigh cells that could be exploited for cancer 
stem cell-targeted therapy.  These potential therapeutic targets include the mTOR 
pathway, her-2/neu, CD47 and FGF18. 
 Differential gene expression of ALDHhigh cells from both models indicates 
increased mTOR signaling.  Figure 4.26 shows the mTOR pathway in ALDHhigh 
FNAR-C1 cells compared to ALDHlow FNAR-C1 cells.  The mTOR pathway in 
ALDHhigh taxol-resistant SKOV3 cells relative to ALDHlow SKOV3 cells is displayed 
in Figure 4.27.  The primary mechanism of increased mTOR signaling involved 
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modulation of the tuberous sclerosis complex (TSC), which inhibits mTOR activation 
through RHEB224.  ALDHhigh FNAR-C1 cells inhibited TSC complex activity through 
4.61-fold upregulation of insulin receptor substrate 1 (IRS1)225.  Inhibition of the TSC 
complex in ALDHhigh taxol-resistant SKOV3 cells was achieved with 1.58-fold 
upregulation of PI3K226.  ALDHhigh cells of both models additionally blocked TSC 
inhibition of the mTOR pathway through upregulation of RPS6KB2 (FNAR-C1: 3.23-
fold; SKOV3: 1.55-fold)227.  Not shown in the pathway analysis is ras-related GTP 
binding D (RRAGD), which stimulates the mTOR pathway228.  ALDHhigh cells from 
both models exhibited upregulation of RRAGD (Table 4.2, pg. 98).  The increased 
activity of the mTOR pathway in ALDHhigh cells of both models suggests that 
inhibition of mTOR signaling could eliminate ovarian cancer stem cells.  The mTOR 
inhibitor rapamycin has been administered clinically for more than a decade.  Because 
the clinical safety of rapamycin is well established, clinical testing for the treatment of 
ovarian cancer could proceed rapidly. 
 Ovarian cancer specimens commonly express her-2/neu (ERBB2)229.  
Accordingly, expression of ERBB2 was detected in both models.  FNAR-C1 cells 
showed strong expression in both ALDHhigh and ALDHlow fractions (Table 4.5, pg. 
108).  SKOV3 cells expressed ERBB2 at a sufficiently high level as to suggest 
overexpression.  Furthermore, ALDHhigh taxol-resistant SKOV3 cells displayed a 
slight, but consistent, upregulation of ERBB2 relative to ALDHlow SKOV3 cells 
(Table 4.5, pg. 108).  Because both ALDHhigh populations expressed ERBB2, ERBB2-
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targeted therapy could potentially eliminate ovarian cancer stem cells in patients with 
detectable expression.  Several drugs targeting ERBB2 are currently clinically 
available, which would reduce the time necessary for clinical testing. 
Figure 4.26: FNAR-C1 mTOR Signaling 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh FNAR-C1 cells relative to 




Figure 4.27: SKOV3 mTOR Signaling 
 
Pathway analysis of microarray data.  Data is presented as ALDHhigh taxol-resistant SKOV3 cells 
relative to ALDHlow SKOV3 cells.  Genes shaded in yellow were upregulated and genes shaded in blue 
were downregulated. 
 CD47 prevents phagocytosis by macrophages and is highly expressed in 
normal and malignant stem cells230, 231.  ALDHhigh cells of both models expressed 
higher levels of CD47 than their ALDHlow counterparts (Table 4.2, pg. 99).  
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Accordingly, therapy targeting CD47 could potentially eradicate ovarian cancer stem 
cells.  Preclinical studies suggest that CD47-specific antibodies could effectively treat 
a broad range of cancers, including ovarian cancer232.  Should this treatment strategy 
proceed to clinical use, it may successfully eliminate all populations of ovarian cancer 
cells. 
Both ALDHhigh populations exhibited upregulation of fibroblast growth factor 
18 versus their ALDHlow counterparts (FGF18; Table 4.2, pg. 98).  FGF18 primarily 
signals through fibroblast growth factor receptor 3 (FGFR3), which was expressed in 
all populations tested233.  Therefore, FGF18 signaling may serve an important role in 
all populations of ovarian cancer cells, and FGFR3 inhibition might successfully treat 
ovarian cancer stem cells.  Encouragingly, several small molecule inhibitors of FGFR3 




Table 4.2: Common Upregulated Genes (continued on next page) 
Gene Symbol FNAR-C1 Microarray 




SKOV3       
PCR 
NOV 100.842  2.226  
ALDH1A2 86.522 325.761   
ALDH1A1   23.699 44.494 
FBN2 32.256  1.592  
ANGPTL4 17.557 31.900 2.621 3.511 
ABCB1B 
(MDR1) 16.797 24.603   
ABCB1 
(MDR1)   3.743 374.276 
FRAS1 5.665  2.143  
TM7SF2 5.444  2.105  
MAL2 5.390  10.221  
PLCE1 5.294  1.620  
CTSC 4.447  1.521  
HIST3H2A 4.349  1.647  
CHKA 4.302  2.703  
SUV420H1 3.948  1.531  
OLR1 3.869  2.859  
CXADR 3.734  4.441  
RRAGD 3.467  2.309  
RPS6KB2 3.225  1.551  
NDUFV1 3.187  1.616  
KRT19 3.183  2.153  
TFPI 3.102 3.850 4.702 5.129 
EDN2 3.082  2.318  
CFH 3.030  2.867  
COX8A 3.007  1.785  
FGF18 2.912 3.793 1.778 3.775 
CFB 2.848  1.515  
DAB2 2.834  2.320  
TRPT1 2.789  1.617  
SPRY1 2.786  2.012  
PXDN 2.776  2.431  
ASNS 2.768  2.191  
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Table 4.2 Continued: Common Upregulated Genes 
Gene Symbol FNAR-C1 Microarray 




SKOV3       
PCR 
AGRN 2.757  1.789  
EYA4 2.746  1.704  
WBP5 2.679  2.955  
MTUS1 2.655  1.580  
COL5A2 2.603  2.384  
ECH1 2.600  1.795  
CTSD 2.582  2.282  
RTN3 2.568  1.791  
ANXA1 2.557 2.745 1.576 1.488 
NGFRAP1 2.373  1.865  
NAPRT1 2.353  1.705  
FLOT1 2.311  1.699  
CTTN 2.295  1.571  
RHOBTB3 2.282  3.038  
SDPR 2.274  4.977  
GCA 2.257  1.771  
IL1R2 2.176  2.398  
PIK3R1 2.119  1.580  
STX3 2.090  1.627  
CD47 2.088 1.961 1.827 2.079 
PPP2R2B 2.074  2.108 183.615 
ITPKA 2.072  1.605  
EIF4A2 2.064  1.780  
HEXB 2.034  1.692  
APLP2 2.025  1.996  
AIF1L 2.018  1.546  
MRPL23 2.003  1.620  
This table lists all genes that were upregulated in both models along with fold-change values from 
microarray and PCR analyses.  Empty cells signify that the gene was not tested with that assay.  FNAR-
C1 data is presented as ALDHhigh FNAR-C1 cells versus ALDHlow FNAR-C1 cells.  SKOV3 data is 
presented as ALDHhigh taxol-resistant SKOV3 cells versus ALDHlow SKOV3 cells. 
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Table 4.3: Common Downregulated Genes (continued on next page) 







LAMB3 -30.654  -1.682  
KCNN4 -25.750  -2.313  
PLAC8 -18.015  -2.993  
NQO1 -14.447  -1.821  
LAMC2 -11.326  -3.648  
CDA -8.878  -6.756 -776.822 
TUBB3 -8.845 -20.000 -6.735 -10.526 
ANXA8/ANXA8L1 -7.870  -1.951  
TGFBI -6.848 -6.250 -25.686 -90.909 
SFN -6.696  -3.786 -11.494 
COL17A1 -5.623  -3.033  
SCD -5.517  -1.649  
ALDH4A1 -5.182  -1.553  
ANKRD37 -5.095  -1.517  
UAP1 -5.000  -1.574  
SGK1 -4.978  -6.039  
HMOX1 -4.582 -5.155 -2.241 -18.868 
PCOLCE2 -4.360  -1.977  
P4HA2 -4.167  -2.509  
TSPAN13 -4.007  -1.933  
GCNT1 -3.678  -2.538  
CCDC92 -3.672  -1.948  
TGFBR2 -3.432 -2.114 -2.691 -12.987 
HSPB1 -3.391  -1.994  
FSTL3 -3.277 -12.500 -1.936 -3.115 
ALDOC -3.224  -1.858  
PTHLH -3.211  -1.910  
CLIC3 -3.191  -2.056  
HOMER2 -3.112  -1.631  
MT2A -3.107  -2.094  
PFKP -3.098  -1.904  
TUBA4A -3.070 -3.030 -6.257 -33.333 
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Table 4.3 Continued: Common Downregulated Genes 







UBL3 -3.031  -1.758  
SLC2A1 -2.958  -3.406  
SNAI2 -2.909  -4.370  
VIM -2.901 -3.300 -2.798 -4.000 
SAT1 -2.896  -1.533  
ELL2 -2.721  -1.551  
PKM2 -2.684  -1.798  
NET1 -2.647  -1.513  
AK4 -2.634  -2.641  
PLAUR -2.626 -2.667 -2.711 -9.346 
RNPEP -2.552  -1.825  
NUDT5 -2.509  -1.896  
FXYD5 -2.449 -2.096 -3.708 -4.630 
PGK1 -2.369  -1.903  
PAQR4 -2.312  -1.721  
KRT17 -2.274  -2.321  
TBC1D2 -2.259  -2.100  
LDHA -2.254  -2.096  
MAOA -2.223  -1.622  
RGS2 -2.099  -2.161  
BNIP3 -2.068  -3.836  
UGT1A6 -2.053  -1.780  
HDGF -2.030  -1.612  
ANKRD57 -2.018  -2.037  
This table lists all genes that were downregulated in both models along with fold-change values from 
microarray and PCR analyses.  Empty cells signify that the gene was not tested with that assay.  FNAR-
C1 data is presented as ALDHhigh FNAR-C1 cells versus ALDHlow FNAR-C1 cells.  SKOV3 data is 





Table 4.4: Commonly Regulated Gene Families (continued on next 5 pages) 
Gene FNAR-C1 SKOV3 Function 
Kruppel-Like Factor 
KLF2  -1.932 Differentiation 
KLF4 -4.256  Differentiation; tumor suppressor 
KLF6  -2.039 Tumor suppressor 
S100 Calcium Binding Protein 
S100A2  -4.856 
S100A11  -1.814 Tumor suppressor 
Epithelial Membrane Protein 
EMP2 -3.937  
EMP3  -4.642 
Cell proliferation; cell-cell 
interactions; tumor suppressor 
Bone Morphogenetic Protein 
BMP4  5.671 
BMP7 4.454 (3.329) 
 Cancer invasion 
Cadherin 
CDH11 4.150  Cancer invasion 
CDH16  -1.590 
CDH17 -10.845  
Functionally related cell-cell 
adhesion molecules 
Protein Tyrosine Kinase 
PTK2  1.538 
PTK7 3.609  
Cell adhesion molecule; cell 
migration; proliferation and 
apoptosis; angiogenesis 
Matrix Metallopeptidase 
MMP2 3.137 ()  
MMP7  1.927 (8.823) 
MMP14 2.610 (3.274) 
 
Extracellular matrix degradation; 
cancer invasion 
Insulin-Like Growth Factor Binding Protein 
IGFBP4 -5.651  
IGFBP3  -2.366 
Enhancer of apoptosis in malignant 
prostate cells 
ADAM Metallopeptidase Domain 
ADAM15 -4.114  
ADAM19  -3.034 
ADAM23 -6.454  




Table 4.4 Continued: Commonly Regulated Gene Families  
Gene FNAR-C1 SKOV3 Function 
Doublecortin-Like Kinase 
DCLK1  -1.544 
DCLK3 -2.795  Neuronal migration 
Semaphorin 
SEMA3B  2.194 
SEMA3D 6.965  Tumor suppressor 
Vascular Endothelial Growth Factor 
VEGFA -3.660 (-5.348) 
 
VEGFC  -1.524 
Vasculogenesis; angiogenesis; 
endothelial cell growth/migration 
Serpin Peptidase Inhibitor 
SERPINB6 -2.640  
SERPINB8 -4.538  
SERPINC1 -4.741 (-3.676) 
 
SERPINE1  -5.692 (-32.258) 
Coagulation 
SERPINB2 -4.340 (-3.546) 
 
SERPINE1  -5.692 (-32.258) 
Inhibition of extracellular matrix 
degradation 
Collagen 
COL5A2 2.603 2.384 
COL24A1 2.778  









COL14A1 -4.909  
Basement membrane 
Cathepsin 
CTSL1  -3.390 





Table 4.4 Continued: Commonly Regulated Gene Families 
Gene FNAR-C1 SKOV3 Function 
Keratin 
KRT19 3.183 2.153 
KRT15 11.738  Structural integrity of epithelial cells 
KRT34  -1.565 
KRT31 -3.487  
Structural constituent of cytoskeleton 
activity 
Kelch-Like Family Member 
KLHL2 2.538  
KLHL5  1.547 
Organizing the actin cytoskeleton of 
the brain cells 
Tubulin 
TUBA1A  -1.679 
TUBA8 -3.601  Constituent of microtubules 
TUBA4A -3.070 (-3.030) 
-6.257 
(-33.333) 
TUBB2A -19.737  







TPM1  -1.628  
TPM2 -13.703   
TPM3  -1.908  
RAS Oncogene Family 
RAB1B 2.689  
RAB36 5.053  
RAB38  1.527 
ER, Golgi transport 
RAB7A  1.840 
RAB36 5.053  
RAB38  1.527 
RIN2 4.260  
RAB31  2.160 
Endocytosis 
RAS 
RASA1  -2.241 




Table 4.4 Continued: Commonly Regulated Gene Families 
Gene FNAR-C1 SKOV3 Function 
Copine 
CPNE7 3.118  
CPNE8  1.559 
Calcium-dependent, phospholipid 
binding protein, membrane 






Androgen metabolism; source of 
retinoic acid 
CYP3A5 3.149  Metabolism of intra-prostatic androgens 
CYP26B1 -12.803  Specific inactivation of all-trans-retinoic acid 
DNA-Damage-Inducible Transcript 
DDIT4  -2.967 
DDIT4L -12.820  Inhibition of MTOR activity 
Nuclear Receptor Subfamily 1, Group H 
NR1H4 2.699  
NR1H3  1.570 Cholesterol transport & metabolism 
ATP-Binding Cassette, Subfamily A 
ABCA1  -2.747 
ABCA7 -2.862  Lipid efflux 
Solute Carrier Family 
SLC16A5  1.893 
SLC16A11 3.183  Monocarboxylic acid transporter 
SLC22A1 -3.740  
SLC22A2  -1.677 
SLC22A18 -3.667  
Organic cation transporter 
Microsomal Glutathione S-Transferase 
MGST1 6.948  Protecting cells from cytostatic drugs 
MGST2  2.919 
MGST3 2.737  Leukotriene biosynthesis 
Glutathione S-Transferase 
GSTA2 2.609  
GSTM1  1.731 (**) 
Conjugating reduced glutathione to a 





Table 4.4 Continued: Commonly Regulated Gene Families 
Gene FNAR-C1 SKOV3 Function 
Dimethylarginine Dimethylaminohydrolase 
DDAH1  1.690 
DDAH2 3.598  
Regulating cellular concentration of 
demethylargenines 
Phospholipase C 
PLCB1 2.764  
PLCE1 5.294 1.620 
Hydrolysis of phosphatidylinositol 
4,5 biphosphate to generate 
diacylglycerol and inositol 1,4,5 
triphosphate 
Caspase 
CASP3  1.686 
CASP4  1.606 
CASP7 2.677  
Cysteine containing aspartate-specific 
protease; apoptosis 
1-Acylglycerol-3-Phosphate O-Acyltransferase 
AGPAT4  -1.566 
AGPAT9 -2.604  Phospholipid biosynthesis 
Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 
DYRK2  -1.608 
DYRK3 -3.081  
Serine/threonine and tyrosine kinase; 
phosphorylating histone H2B; cell 
growth and development 
Hexokinase 
HK1  -1.609 
HK2 -3.287  
Phosphorylating glucose to produce 
glucose-6-phosphate 
Gap Junction Protein 
GJA1  -2.173 (-11.905) 
GJA5 -3.752  
GJB2 -768.740  
Formation of gap junctions 
Transglutaminase 
TGM2  -2.002 
TGM5 -3.813  
Cross-linking of proteins; signal 
transduction; guanosine triphosphate 
hydrolysis 
Glutathione Peroxidase 
GPX2 -4.330  
GPX8  -1.631 Formation of glutathione disulfide 
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Table 4.4 Continued: Commonly Regulated Gene Families 
Gene FNAR-C1 SKOV3 Function 
Phosphodiesterase 
PDE5A 6.074  
PDE9A  1.887 Inactivation of cGMP 
Receptor Tyrosine Kinase-Like Orphan Receptor 
ROR1  1.548 
ROR2 4.119  Functionally redundant 
Cysteine and Glycine-Rich Protein 
CSRP2 3.871   
CSR2BP  1.576  
This table lists members of gene families with similar function that are consistently differentially 
regulated in both models by microarray.  Fold change values from microarray analysis are presented 
and fold-change values from PCR analysis are shown in parenthesis.  Arrows denote direction of 
change when fold-change values cannot be calculated because one sample is undetectable by PCR.  ** 
Denotes genes undetectable by PCR in both samples.  FNAR-C1 data is presented as ALDHhigh FNAR-
C1 cells versus ALDHlow FNAR-C1 cells.  SKOV3 data is presented as ALDHhigh taxol-resistant 
SKOV3 cells versus ALDHlow SKOV3 cells. 
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Table 4.5: Previously Reported Ovarian Cancer Stem Cell Markers, Hormone 









CD24 -1.763 -1.560 -9.458 -41.667 
CD44 -21.481 -22.727 -1.188 -1.003 
KIT 1.289 10.644 -1.968 -333.333 
CD133 
(PROM1) -1.009  -1.026 1.38 
ESR1 1.062 -2.101 1.126 2.544 
PGR 1.306 123.991 -1.032  
AR  3.073 1.029 -1.242 
FSHR 1.140 ** 1.022  
LHCGR -1.008 ** 1.036  
ERBB2 
(her-2/neu) 
-1.040 -1.147 1.320 1.308 
MUC16 
(CA125) 5.241 13.157 -1.078 
 
ABCC1 -2.120 -2.421 1.031  
ABCC3 -1.051  2.207 1.652 
ABCG2 -1.462 -1.242 1.377 20.030 
TERC 1.015  1.037 1.779 
TERT 1.111 1.561 -1.046 -7.936 
DKC1 -1.618  -1.355  
TEP1 -1.369 -1.179 1.014 -2.421 
This table lists genes important in cancer stem cells or ovarian cancer along with fold-change values 
from microarray and PCR.  FNAR-C1 data is presented as ALDHhigh FNAR-C1 cells versus ALDHlow 
FNAR-C1 cells.  SKOV3 data is presented as ALDHhigh taxol-resistant SKOV3 cells versus ALDHlow 
SKOV3 cells.  Arrows signify direction of change when gene was undetectable in one sample.  ** 
Signifies that the gene was not detectable in either sample.  Empty cells signify that the gene was not 













ALDHhigh Cells Represent Ovarian Cancer Stem Cells 
The cancer stem cell hypothesis proposes that, although altered, the 
differentiation hierarchy of malignancies remains intact with rare stem cell 
populations giving rise to the differentiated progeny that comprise the bulk of the 
tumor.  Cancer stem cells have been identified in many cancers, and these cells have 
been proposed to initiate metastases and relapse.  This project identified putative 
ovarian cancer stem cells based on high aldehyde dehydrogenase 1 (ALDH1) activity 
in two models of ovarian cancer.  The first model was the FNAR-C1 rat model of 
ovarian cancer, which most closely resembles an endometrioid carcinoma.  One 
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benefit of this model is that it originated from a spontaneous tumor and therefore does 
not have artificial genetic manipulation.  It can also be readily transplanted into 
immunocompetent Lewis rats, which may be more representative than xenografts into 
immunodeficient mice.  Although the endometrioid subtype is a less aggressive 
subtype, it would be ideal to identify a marker that isolates ovarian cancer stem cells 
in all ovarian cancer subtypes234.   
In order to control for species or subtype differences, the human SKOV3 cell 
line was also studied.  The initial report of the SKOV3 cell line did not describe the 
subtype235.  Subsequent analyses described SKOV3 cells as both serous and clear cell 
subtypes76, 77.  The serous subtype is the most common form of ovarian cancer, 
representing approximately 70% of cases236.  Meanwhile, only 10% of ovarian cancer 
cases are of the clear cell subtype236.  When stratified by stage, serous and clear cell 
subtypes have similar prognoses; however, patients with the serous subtype are much 
less likely to present in stage I than those with the clear cell subtype236, 237.  Despite the 
uncertain histological subtype represented by SKOV3 cells, this model is distinct from 
the endometrioid subtype of FNAR-C1 cells.  Therefore, the use of these two models 
should allow for identification of ovarian cancer stem cells across all subtypes.   
High ALDH1 activity (ALDHhigh) is strongly associated with stem cells and 
chemoresistant cells62, 238, 239.  Additionally, multiple types of cancer stem cells have 
been reported to possess high ALDH1 enzyme activity20, 63-65, 67, 74.  For these reasons, 
ovarian cancer cells were isolated based on ALDH1 activity and examined for stem 
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cell characteristics.  Cells cultured in medium containing serum (referred to as 
differentiation medium) lacked a distinct ALDHhigh population (Figure 4.1A, C).  In 
order to study ALDHhigh cells, it was necessary to culture cells in medium that 
supported the expansion of undifferentiated cells (KnockOut medium).  FNAR-C1 
cells maintained in KnockOut medium possessed a distinct ALDHhigh population 
(Figure 4.1B).  SKOV3 cells, on the other hand, remained ALDHlow (data not shown).  
Examination of a taxol-resistant SKOV3 subline showed a prominent ALDHhigh 
population (Figure 4.1D).  To further expand this population, taxol-resistant SKOV3 
cells were cultured in KnockOut medium (Figure 4.1E).  Using these conditions 
permitted the comparison of ALDHhigh and ALDHlow populations from both models. 
A concern of comparing cells from distinct culture conditions is that 
differences between the two populations may be due to biology or the differing media.  
However, less than ten percent of differentially regulated genes were consistent 
between the two models.  Because so few genes were consistently differentially 
regulated, the observed differences between ALDHhigh and ALDHlow cells is likely to 
be due to the underlying biology of the cells.  An additional concern is comparing 
taxol-resistant to taxol-sensitive SKOV3 cells, as this could identify differences due to 
drug resistance rather than a stem cell phenotype.  To control for this, microarray data 
from the SKOV3 model was compared to the FNAR-C1 model, which had not 
undergone drug selection.  Only those differences that were consistent between the 
two models were presented thus eliminating differences due to drug resistance alone.  
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Moreover, taxol-resistant SKOV3 cells displayed resistance to additional drugs with 
different mechanisms of resistance, which makes it unlikely that the taxol resistance 
per se was responsible for the observed biological differences 
With the populations identified, it became possible to test the hypothesis that 
cells with high ALDH1 activity have a stem cell phenotype.  The first category of 
stem cell properties examined was growth characteristics, which included nonadherent 
growth, relative quiescence and lacking contact inhibition.  ALDHhigh cells displayed 
an absence of contact inhibition with the formation of nodules, which were not seen in 
ALDHlow cells (Figure 4.2A).  The capacity for nonadherent growth, as shown through 
the formation of spheroids, was also restricted to the ALDHhigh population (Figure 
4.2B, C).  Gene expression analysis showed a block at the G1/S checkpoint in 
ALDHhigh cells (Figures 4.6 and 4.7).  Because of this, the ALDHhigh population 
contained fewer dividing cells than the ALDHlow population (Figure 4.5) resulting in a 
slower growth rate (Figure 4.4).  Taken together, ALDHhigh cells were more quiescent 
than their ALDHlow counterparts.  Overall, ALDHhigh cells possessed growth 
characteristics consistent with a stem cell phenotype. 
Cancer stem cells are hypothesized to possess additional biological features, 
such as smaller size, the ability to regenerate the phenotypic diversity of the tumor, 
self-renewal, increased tumorigenicity, and drug resistance127-133.  ALDHhigh cells were 
smaller in size than their ALDHlow counterparts, which may be due to their relative 
quiescence (Figure 4.3).  ALDHhigh cells were the only population able to produce 
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both ALDHhigh and ALDHlow cells, thus regenerating the phenotypic diversity of the 
cell line (Figures 4.8 and 4.9).  This indicates the loss of ALDH1 activity concurrent 
with differentiation.  The expansion of ALDHhigh cells additionally suggests the 
capacity for self-renewal.  Tumorigenicity was confined to the ALDHhigh population 
(Table 4.1).  Exposure to drugs with different mechanisms of action and resistance 
revealed multi-drug resistance in ALDHhigh cells (Figure 4.10)144, 240-247.  Additionally, 
culture with taxol increased the percentage of ALDHhigh cells (Figure 4.11).  
Therefore, ALDHhigh cells display biological characteristics of stem cells. 
Gene expression patterns may also indicate a stem cell phenotype (Figures 
4.12 to 4.15).  ALDHhigh cells expressed higher levels of genes commonly restricted to 
stem cells and lower levels of genes associated with differentiation.  Differential gene 
expression suggested the capacity for self-renewal in ALDHhigh cells.  Genes 
associated with the maintenance of pluripotency were upregulated in ALDHhigh cells 
as were genes involved in quiescence.  ALDHhigh cells also exhibited upregulation of 
genes important for stem or progenitor cell proliferation.  Thus, differential gene 
expression in ALDHhigh cells further supports the conclusion that this population 
represents ovarian cancer stem cells. 
Since ALDHhigh cells displayed numerous cancer stem cell properties, analysis 
of ALDHhigh cells may reveal properties of ovarian cancer stem cells.  Because of its 
comprehensive nature, microarray analysis was employed to compare ALDHhigh and 
ALDHlow cells, and real-time qRT-PCR of individual genes was performed to validate 
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the findings.  By better understanding the biology of ovarian cancer stem cells, 
targeted therapeutics can be developed in order to improve patient outcomes. 
ALDHhigh Cells Represent a Biologically Distinct Population 
 Differential gene expression indicated increased tight junction signaling in 
ALDHhigh cells (Figures 4.16 and 4.17).  Transmembrane components of tight 
junctions were upregulated as well as intracellular signaling molecules.  The increased 
tendency of ALDHhigh cells to form tight junctions may explain the observed 
formation of spheroids by these cells (Figure 4.2B, C)248, 249.  Decreased cell cycle 
progression appears to be one result of these junctions.  Junctional adhesion molecule 
3 (JAM3) binds cingulin, which inhibits cell cycle progression by binding to Rho/Rac 
guanine nucleotide exchange factor 2 (ARHGEF2)250, 251.  Both models showed 
differential regulation of the components of these interactions.  ALDHhigh FNAR-C1 
cells expressed increased levels of JAM3.  Conversely, ALDHhigh taxol-resistant 
SKOV3 cells exhibited upregulation of cingulin and downregulation of ARHGEF2.  
This signaling interaction may provide a mechanism for contact inhibition.  
Intriguingly, ALDHhigh cells in nodules and spheroids continue to proliferate, albeit at 
a very slow rate, suggesting that some Aldefluor high cells escape this growth 
inhibition. 
 Ovarian cancer stem cells have been proposed to be responsible for invasion 
and metastasis.  Differential gene expression in ALDHhigh cells provides support for 
this hypothesis (Table 4.4).  ALDHhigh cells showed downregulation of multiple tumor 
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suppressor genes, indicating a more malignant phenotype with increased proliferation, 
migration and invasion173, 177, 252-256.  In addition to the loss of tumor suppressor genes, 
ALDHhigh cells exhibited upregulation of genes contributing to invasion, including 
enzymes responsible for extracellular matrix degradation.  Not only were degradation 
enzymes upregulated, but inhibitors of degradation were also downregulated.  Further 
permitting invasion, ALDHhigh cells downregulated basement membrane deposition.  
Taken together, ALDHhigh cells demonstrated an increased capacity for migration and 
invasion compared to ALDHlow cells.  One route for dissemination of cancer cells is 
the vascular system.  Activation of the extrinsic pathway of the coagulation cascade 
could potentially inhibit this migration.  Tissue factor pathway inhibitor (TFPI) 
inhibits the initiation of the extrinsic pathway and was upregulated in ALDHhigh cells 
(Table 4.2, Figure 4.18 and Figure 4.19).  Combined with increased invasiveness, the 
prevention of coagulation observed in ALDHhigh cells indicates an ability to enter the 
blood and lead to distant metastases.  Overall, differential gene expression in 
ALDHhigh cells supports the hypothesis that ovarian cancer stem cells are more 
malignant than their differentiated counterparts and represent the cell population 
capable of migration, invasion and metastasis. 
ALDHhigh Cells Have Inconsistent Expression of Previously Reported Ovarian 
Cancer Stem Cell Markers 
 In addition to high ALDH1 activity, other markers have been reported to 
identify ovarian cancer stem cells, including CD24, CD44, KIT and CD133.  Because 
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most studies only examine one marker, it is not known if these varied markers identify 
the same cell population.  This project permitted the evaluation of marker expression 
levels in ALDHhigh and ALDHlow cells from two different ovarian cancer subtypes.  
CD24 was the only marker to show consistent differential expression between the two 
models (Table 4.5).  Previous reports disagree as to whether ovarian cancer stem cells 
express CD24 to a greater or lesser degree than their differentiated progeny46, 59.  Data 
presented here indicated reduced CD24 expression in ovarian cancer stem cells.  
However, all populations showed strong expression of CD24, potentially limiting the 
usefulness of this marker for isolation.  Variable expression of CD44 and KIT have 
been reported for putative ovarian cancer stem cells and this study confirmed 
previously reported variability29, 35, 37, 61.  CD44 was downregulated in ALDHhigh 
FNAR-C1 cells but unchanged in ALDHhigh taxol-resistant SKOV3 cells.  KIT was 
upregulated in ALDHhigh FNAR-C1 cells but downregulated in ALDHhigh taxol-
resistant SKOV3 cells.  Despite reports of CD133 expression on ovarian cancer stem 
cells, only 30-70% of ovarian cancer specimens express detectable levels of CD13355, 
56.  Expression of CD133 could not be reliably detected in any population tested.  
Therefore, the only previously reported ovarian cancer stem cell marker to be 
consistently differentially regulated in ALDHhigh cells was CD24. 
 The differentiation hierarchy of normal solid tissues is poorly understood, 
which complicates studies of cancer stem cells in solid tumors.  The reason for such 
varied reports of ovarian cancer stem cell markers is unclear.  It is possible that 
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differentiation proceeds through several stages and each marker identifies a particular 
stage.  Furthermore, ovarian cancer is a collection of diseases with different subtypes, 
and some markers may be subtype-specific.  This project benefits from the study of 
two distinct subtypes to control for this possibility.  Alternatively, heterogeneity 
between patients may yield inconsistent results.  Further study is necessary to 
distinguish between the potential explanations for marker variability. 
No Consistent Differential Regulation of Hormone Receptors in ALDHhigh Cells 
 Steroid hormones are often used as prognostic indicators in ovarian cancer, and 
hormone therapy has been proposed as a treatment strategy.  Therefore, expression of 
hormone receptors in ovarian cancer stem cells could have implications for clinical 
evaluation and treatment.  Estrogen receptor α (ESR1) was differentially regulated in 
both models, but in opposite directions (Table 4.5).  Although expression was low 
overall, both ALDHhigh populations expressed detectable levels of ESR1.  This 
indicates variability in ESR1 expression in ovarian cancer stem cells relative to 
differentiated cells.  However, ovarian cancer stem cells likely express ESR1 at 
sufficient levels for hormone therapy to be effective.  Like ESR1, progesterone 
receptor (PGR) showed conflicting directions of differential regulation in the two 
models (Table 4.5).  In contrast to ESR1, PGR did not show detectable expression in 
ALDHhigh taxol-resistant SKOV3 cells suggesting that PGR may not be expressed in 
all ovarian cancer stem cells.  Androgen receptor (AR) expression could not be 
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reliably detected in any population (Figure 4.5).  It is not clear why FNAR-C1 cells 
showed expression of AR by flow cytometry but not by PCR (Figure 2.3).  However, 
due to upregulation of cytochrome P450 genes that inactivate testosterone, it appears 
that androgen signaling may not be active in ALDHhigh cells (CYP3A5 in FNAR-C1 
and CYP1B1 in SKOV3; Table 4.4, pg. 104)257, 258.  Overall, no consistent differences 
in hormone receptor expression were seen in ALDHhigh cells, which indicates variable 
expression in ovarian cancer stem cells. 
Gonadotropin signaling has been implicated in ovarian cancer progression, and 
gonadotropin-targeted therapies have been proposed.  Consequently, gonadotropin 
receptor expression in ovarian cancer stem cells may have clinical implications.  
Gonadotropin receptors were infrequently expressed and when expressed did not show 
differential expression in ALDHhigh cells.  Follicle stimulating hormone receptor 
(FSHR) was only detected in FNAR-C1 cells (Table 4.5).  Luteinizing 
hormone/choriogonadotropin receptor (LHCGR) was not expressed in any population 
tested (Table 4.5).  Therefore, any therapy targeting gonadotropin receptors would be 
unlikely to reliably eliminate ovarian cancer stem cells. 
 Although not hormone or gonadotropin receptors, her-2/neu (ERBB2) and 
CA125 (MUC16) have implications for ovarian cancer prognosis, necessitating 
evaluation of their expression in ovarian cancer stem cell.  Similarly high levels of 
ERBB2 expression were detected in ALDHhigh and ALDHlow FNAR-C1 cells (Table 
4.5).  SKOV3 cells exhibited extremely high levels of ERBB2 expression, suggesting 
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overexpression.  Additionally, ALDHhigh taxol-resistant SKOV3 cells displayed a 
slight, but consistent, upregulation of ERBB2 (Table 4.5).  Overall, these data suggest 
that ovarian cancer stem cells consistently express ERBB2 at a similar level as the rest 
of the tumor.  Therefore, any prognostic or therapeutic application for ERBB2 should 
be unaffected by the presence of ovarian cancer stem cells.  CA125 is used clinically 
to evaluate response to therapy and relapse.  FNAR-C1 cells showed modest 
expression of CA125 with upregulation in ALDHhigh cells (Table 4.5).  Both 
populations of SKOV3 cells showed consistent, low levels of CA125 expression 
(Table 4.5).  This implies that ovarian cancer stem cells express CA125 and should not 
interfere with clinical measurements. 
Upregulation of MDR1, But Not Other ABC Transporters, In ALDHhigh Cells 
 Expression of ATP-binding cassette (ABC) transporters has been proposed as a 
specific feature of stem cells.  The only ABC transporter that was consistently 
upregulated in ALDHhigh cells was multidrug resistance protein 1 (MDR1; ABCB1B 
in rats, ABCB1 in humans; Table 4.2).  MDR1 prevents the intracellular accumulation 
of a broad class of drugs, including taxol, which may account for the observed taxol 
resistance in ALDHhigh cells.  The multidrug resistance-associated protein subfamily 
(ABCC_) also causes drug resistance.  ABCC1 was downregulated in ALDHhigh 
FNAR-C1 cells, but still highly expressed (Table 4.5).  SKOV3 cells, on the other 
hand, showed similar, low levels of ABCC1 expression in both populations (Table 
4.5).  Conversely, both populations of SKOV3 cells showed high levels of ABCC3 
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expression, despite upregulation in ALDHhigh taxol-resistant SKOV3 cells (Table 4.5).  
Both ALDHhigh and ALDHlow FNAR-C1 cells exhibited modest ABCC3 expression 
without differential regulation (Table 4.5).  Therefore, each model showed strong 
expression with differential regulation of one member of the multidrug resistance-
associated protein subfamily, but neither of these differentially regulated genes were 
consistent between the two models.  The side population phenotype that is often used 
to enrich for stem cells is attributed to ABCG2 expression.  Only ALDHhigh taxol-
resistant SKOV3 cells showed upregulation of ABCG2 (Table 4.5).  Similarly high 
levels of ABCG2 expression were observed in both populations of FNAR-C1 cells 
(Table 4.5).  Accordingly, expression of ABCG2 was consistently found in ALDHhigh 
cells, but variable in ALDHlow cells.  Overall, ovarian cancer stem cells likely express 
variable levels of ABC transporters and those that are consistent may be clinically 
relevant. 
Telomere Maintenance Is Due To Alternative Lengthening of Telomeres 
 The gene components of telomerase showed variable levels of expression and 
inconsistent differential regulation (Table 4.5).  This suggests that telomerase is 
unlikely to be responsible for telomere maintenance in ALDHhigh cells.  Instead, 
microarray data suggested that alternative lengthening of telomeres might be the 
mechanism for telomere maintenance (data not shown).  Many genes reportedly  
involved in alternative lengthening of telomeres showed high levels of expression in 
all populations studied, including the MRN complex (MRE11A, RAD50 and NBN), 
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proteins that prevent telomere shortening (FEN1, MUS81 and FANCD2), and 
additional components (TERF1, TERF2, TINF2 and TERF2IP)259-263.  ALDHhigh 
FNAR-C1 cells showed some upregulation of these genes, including SMC5 (3.226-
fold), FEN1 (3.295-fold) and MUS81 (2.058-fold).  Functionally though, alternative 
lengthening of telomeres likely occurs in both ALDHhigh and ALDHlow cells.  Because 
all cells were expanded in vitro, all populations required maintenance of telomere 
length.  In order to determine mechanisms of telomere maintenance in ovarian cancer 
stem cells, primary tumors must be analyzed. 
Developmental Pathways Are Not Consistently Active In ALDHhigh Cells 
While the importance of developmental pathways in embryonic development 
has been well established, recent evidence indicates a role for developmental pathways 
in normal and malignant adult stem cells as well264-271.  The NFκB, Wnt/β-catenin and 
Notch pathways showed differential regulation in both models, but with different 
effects.  Differential regulation in ALDHhigh FNAR-C1 cells indicated active NFκB 
and Wnt/β-catenin pathways but decreased Notch signaling (Figures 4.20, 4.22 and 
4.24).  In contrast, ALDHhigh taxol-resistant SKOV3 cells exhibited increased Notch 
signaling but downregulated NFκB and Wnt/β-catenin signaling (Figures 4.21, 4.23 
and 4.25).  Neither model displayed differential regulation of the Hedgehog pathway.  
This suggests that developmental pathways may have the dual functions of stem cell 
maintenance or differentiation depending on the context of the cell.   
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Potential Ovarian Cancer Stem Cell-Targeted Therapy 
 The ultimate goal of cancer research is to improve patient outcomes.  The 
cancer stem cell hypothesis proposes that eliminating cancer stem cells will lead to 
durable remission.  This study identified potential therapeutic targets on the basis of 
gene expression, including the mTOR pathway, ERBB2, CD47 and FGF18.  Because 
two distinct subtypes were studied, the results found here are more likely to be 
representative of all ovarian cancer stem cells.   
Of the identified potential therapeutic targets, only the mTOR pathway and 
CD47 are expected to be specific for ovarian cancer stem cells.  ALDHhigh cells 
showed increased mTOR activity and upregulation of CD47 compared to ALDHlow 
cells.  In contrast, ERBB2 was highly expressed in all populations.  Although FGF18 
was upregulated in ALDHhigh cells, the secreted protein could act on either ALDHhigh 
or ALDHlow cells, both of which express the specific receptor FGFR3.  While 
targeting ERBB2 or FGFR3 would potentially eliminate ovarian cancer stem cells, 
these treatments would likely also target the differentiated population. 
The potential treatment strategies also differ in clinical drug availability.  
Drugs targeting the mTOR pathway and ERBB2 are already in clinical use, thereby 
permitting a more rapid application of these treatment schemes.  However, ERBB2-
targeted therapy has only been used against cells that overexpress ERBB2, and so it 
remains to be determined if this therapy would also be effective against cells without 
overexpression.  Several FGFR3 inhibitors are in clinical trials, but none has 
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completed phase 3 trials.  Therapy targeting CD47 is still undergoing preclinical 
testing.  Therefore, therapy targeting FGFR3 or CD47 would proceed much more 
slowly than mTOR- or ERBB2-targeted therapies. 
Implications and Future Directions 
 This project contributes a valuable research model for the study of ovarian 
cancer.  The FNAR-C1 model arose from a spontaneous ovarian tumor, so it lacks 
artificial genetic manipulation that may not be representative of the human disease.  
The tumor can be propagated in vitro, allowing for more detailed analysis of the cells.  
The tumor can also be transplanted in vivo into immunocompetent animals, permitting 
investigation of immune system interactions with the cancer.  Additionally, recent 
controversy concerning evaluation of tumorigenicity in immunocompromised animals 
is circumvented with this model.  Finally, the FNAR-C1 model is phenotypically 
consistent with human endometrioid ovarian cancer, making it a reliable model for this 
disease.  Because the endometrioid subtype is not as common or aggressive as the 
serous subtype, fewer models of this subtype exist234.  This project provides a model 
of endometrioid ovarian cancer with the potential to improve understanding of this 
disease. 
 In addition to contributing a novel research model, this project further validates 
the existence of ovarian cancer stem cells as well as the use of high aldehyde 
dehydrogenase activity as an ovarian cancer stem cell marker.  Further research is 
required to elucidate the reason for the variety of proposed ovarian cancer stem cell 
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markers.  This project begins to resolve this concern by demonstrating inconsistent 
expression of all markers except CD24.  This represents the first analysis of multiple 
markers in different subtypes and helps to clarify the value of reported markers.  
Further comparisons remain necessary, ideally in a large cohort of patient samples, in 
order to fully characterize ovarian cancer stem cell markers.   
 Furthermore, this project provides the first comprehensive gene expression 
analysis of ovarian cancer stem cells from two discrete subtypes.  This analysis 
illustrated the variability within ovarian cancer stem cells.  In some cases, each 
achieved the same function but via alternative genes.  In other cases, pathways were 
altered in divergent manners producing diverse properties.  Rarely were gene 
expression differences consistent in both models.  By identifying those genes and 
pathways with consistent expression, potential therapeutic targets were identified.  
Few studies have proposed targets for ovarian cancer stem cell eradication.  Moreover, 
the few treatments that have been presented were not based on thorough analysis of 
independent ovarian cancer stem cell samples and therefore may not be consistently 
effective.  In contrast, the treatments proposed by this analysis would likely target 
ovarian cancer stem cells across multiple subtypes. 
 While this project provides further understanding of ovarian cancer stem cells, 
additional research is necessary.  Gene expression differences require validation via 
functional assays.  These differences must also be confirmed in patient samples, 
ideally in a large cohort that includes all subtypes.  Finally, proposed therapeutic 
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targets need to be tested for effectiveness against ovarian cancer stem cells.  Should 
additional research confirm the results of this study, therapy targeting ovarian cancer 
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